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Abstract 
 
Background: The scale-up of combination antiretroviral therapy (ART), one of the greatest 
pharmacological interventions in human history, has reduced adult HIV-related deaths in 
South Africa by around 70% between the peak in 2005 and 2019, but it is unclear from 
published studies in South Africa and globally which subgroups of HIV-infected adults, defined 
by both baseline and current (time-updated) characteristics, may achieve HIV-uninfected 
levels of mortality and which subgroups have relative mortality that is within the insurance 
industry’s threshold for insurability. Relative mortality estimates are important in insurance 
since insurability is measured by relative mortality, not absolute mortality or other measures 
such as life expectancy. As HIV-infected people survive to increasingly longer durations of 
ART, there is a need for patients, healthcare practitioners, ART programmes, other modellers, 
insurers and policymakers to understand the prognosis when measured from later durations 
on ART based on current characteristics. However, most South African studies are based on 
baseline characteristics, short follow-up times, and low patient volumes, and they lack an HIV-
uninfected control selected from the same subpopulation for estimating relative mortality. At 
the time of initiating this research in 2013/2014, some insurers were declining HIV-infected 
South Africans applying for higher cover amounts spanning the whole of life. Further, other 
chronic conditions such as Type 2 Diabetes (DM2) had already been insurable for many years 
in South Africa. At the same time, the ART Cohort Collaboration (ART-CC) assessed the 
insurability of HIV-infected people starting ART in Europe and issued an urgent call for a 
corresponding study in South Africa. This study responds to this call and, to the author’s 
knowledge, is the first study outside of Europe to assess the insurability of HIV-infected adults 
starting ART by assessing the relative mortality of South African HIV-infected adults initiating 
ART using an HIV-uninfected control (comparator) chosen from the same subpopulation, 
measured from multiple time points on ART using both baseline and current characteristics, 
long follow-up times, significant patient volumes and accurate mortality ascertainment. The 
study identifies patient subgroups with insurable levels of relative risk as well as subgroups 
that attain HIV-uninfected levels of all-cause mortality and is fundamental for evaluating ART 
programmes and for informing evidence-based insurance decisions that are actuarially sound 
and treat insurance customers fairly.  
 
Methods: A retrospective cohort study is performed using patient data from a large medical 
scheme population and Aid for AIDS (AfA), a private sector HIV managed care programme in 
South Africa. Three cohorts are extracted from the same medical scheme population: HIV-
infected adults starting ART, patients with DM2 starting hypoglycaemic therapy, and an HIV-
4 
 
uninfected and DM2-negative control (comparator). Mortality is ascertained via linkage with 
the national death registry. Relative all-cause mortality risk (relative risk) is estimated using a 
generalized linear model (GLM) assuming a Poisson error distribution and with expected 
numbers of deaths based on the control cohort mortality according to age, gender and 
population group specified as an offset. To meet insurers’ needs for estimates of future relative 
risk that remain constant across the policy lifetime and incorporate current characteristics 
nearest to the time of applying for insurance, relative risk is estimated from each 6-month time 
point on ART over the remaining follow-up according to the patient’s length of time on ART at 
the time of applying for insurance, current CD4 count and viral load and baseline CD4 count. 
 
Results: In the HIV cohort, 8,920 deaths were observed recorded in 77,325 patients starting 
ART between 2000 and 2013 followed for 315,341 person years of observation (PYO) (median 
follow-up of 3.23 years [IQR 2.04;5.30]). In the DM2 cohort, 7,970 deaths were recorded in 
67,705 patients starting antihyperglycaemic therapy between 2000 and 2013 followed for 
365,547 PYO (median follow-up of 6.20 years [IQR 3.85;9.53]). In the control, 24,838 deaths 
were recorded in 512,940 patients followed for 3,276,501 PYO. The median CD4 count in the 
overall HIV cohort reached the lower limit of CD4 count in HIV uninfected people (500 cells/µl) 
after 5 years on ART and, after 12 months on ART, 77% of patients were virologically 
suppressed (viral load ≤ 400 copies/ml), increasing to 80% after 10 years on ART. Within the 
first 6 months on ART, 21% of patients attained both a CD4 count above 200 cells/µl and a 
suppressed viral load, increasing to 49% in months 6-12, 68% in years 1-2 and 80% after 10 
years on ART. In the overall HIV cohort, 90% of patients at risk from all time points 6 months 
or later since ART initiation were estimated to have relative risk within the insurance industry 
threshold (<5). Within patients attaining current CD4 counts of 200+ cells/µl and suppressed 
viral loads (≤400 copies/ml) at 6 months on ART or later, 100% of patients at risk corresponded 
to relative risk levels well below the insurance industry threshold (<5). 90% of patients at risk 
from 1 year of ART onwards had a lower or comparable relative risk to the DM2 cohort, 
implying that the majority of patients on ART had comparable relative risk to those with a 
chronic condition that is already insurable. Baseline CD4 count was only prognostic for relative 
risk within the first three years of ART after adjusting for the immunological and virological 
response to ART. Patients attaining a current CD4 count of 200+ cells/µl and a suppressed 
viral load (≤400 copies/ml) had the lowest relative risk, reducing with time on ART and 
approaching 1 after 3 years on ART in the black population group indicating attainment of HIV 
uninfected mortality levels. However, in the non-black population group, relative risk was 1.59 
[95% CI 1.30;1.88] times higher than in the black population group which, while still within the 
insurance industry threshold, is higher than HIV uninfected levels of mortality. A further sub-
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analysis showed that while the immunological and virological response to ART was similar to 
that reported by the ART-CC in Europe, the level of relative risk was similar only in the non-
black population group and the effect of current age on relative risk was strongly modified by 
population group. 
 
Conclusions: The vast majority of this cohort of South African HIV-infected adults starting 
ART have both insurable levels of relative risk and comparable relative risk to DM2 when 
measured from multiple time points on ART by baseline and current characteristics. The only 
subgroup with relative risk exceeding the insurance industry threshold were patients with 
current CD4 counts ˂200 cells/µl and unsuppressed viral loads (˃400 copies/ml). Mortality in 
the vast majority of this cohort attained CD4 counts ≥200 cells/µl and suppressed viral loads 
(≤400 copies/ml) and approached HIV-uninfected levels after 3 years on ART. A novel 
analytics method is presented for modelling relative risk that better meets insurers’ needs than 
existing studies reporting relative risk in defined intervals of ART using dated patient 
characteristics. 
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Preface 
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• International Congress of Actuaries (ICA) (Washington D.C, 2014), the largest global 
actuarial conference, awarded the presentation with a best-paper award (details and the 
presentation are available at the conference website); 
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Since the publication of the research in 2014, multiple insurers in South Africa, Europe and 
North America have utilised the research with demonstrable success in further increasing 
access to insurance for people living with HIV on significantly more evidence-based and 
affordable terms. 
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1 Protocol 
 
1.1 Background 
 
1.1.1 HIV pandemic: dramatic improvements in the prognosis on ART 
 
Over 38 years since the Acquired Immune Deficiency Syndrome (AIDS) was first recognised 
as a new disease in 1981 [1] and its subsequent identification in 1983 [2-5] and the naming in 
1986 [6] of, the Human Immunodeficiency Virus (HIV) as the causative agent of AIDS, HIV 
continues to be a significant contributor to the global burden of disease [7, 8]. In 2017, 36.9 
million people globally were estimated to be living with HIV [9]. Since the start of the epidemic, 
77.3 million people have been infected with HIV and 35.4 million have died from HIV-related 
illnesses [9]. The projected cumulative HIV-related death toll at 2030 of 40 – 60 million, 
depending on whether the 90-90-90 targets of the UNAIDS 2016-2021 strategy [10] and the 
Sustainable Development Goals [11] are achieved, makes HIV the worst pandemic in recent 
times. 
 
However, since 1996 the widespread use of combination antiretroviral therapy (ART) based 
on three or more antiretroviral (ARV) drugs, including either a non-nucleoside reverse 
transcriptase inhibitor (NNRTI), protease inhibitor (PI), or integrase inhibitor (II), has 
dramatically improved the prognosis of HIV-infected people in both low- and middle-income 
countries (LMIC) and developed countries, transforming a fatal disease into a manageable 
chronic condition [12-29]. ART suppresses replication of HIV, reducing the viral load and 
resulting in an increasing CD4 count and decreasing mortality [30]. Since the peak in 2004, 
HIV-related deaths have been reduced by 51% globally [9] and 62% in Eastern and Southern 
Africa [31]. In South Africa in 2019, HIV-related deaths are estimated to have been reduced 
by 71% since the peak in 2005 and 4.77 million people are estimated to be on ART, more than 
a 700-fold increase since 2001 [32]. From 1995-2013, ART is estimated to have averted 7.6 
million HIV-related deaths globally, including 4.8 million deaths in sub-Saharan Africa [33] – 
by all accounts, the scale-up of ART represents one of the greatest pharmacological 
interventions in human history. 
 
Several studies in resource-rich countries report that mortality in HIV-infected people on ART 
remains higher than in the general population [34-36], even among individuals who experience 
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a good initial response to ART [37], but that the excess mortality of certain subgroups of 
patients is moderate [34, 36-40]. Other studies identified subgroups of patients on ART with 
similar mortality to that of the general population [41-43] and showed that mortality in some 
patients is comparable with other chronic conditions, such as diabetes mellites type 2 (DM2) 
[44-49]. These comparisons are important to improve the understanding of the treatment of 
HIV, to monitor and predict future changes in the HIV epidemic, to plan healthcare services 
and to continue expanding the insurability of HIV. Further, in 2019, South Africa’s progress in 
achieving the 90-90-90 UNAIDS targets is estimated as follows: over 90% of HIV-positive 
people were diagnosed, of which 60% were on ART, of which 53% were estimated to be virally 
suppressed [32]. However, only one European study has assessed the insurability of HIV-
positive people starting ART [50]. There is clearly a need for a South African study to assess 
the insurability of HIV-infected South Africans. 
 
1.1.2 Insurance context 
 
At the time of initiating the study, some insurers were declining insurance applications from or 
offering prohibitive terms to HIV-positive South Africans, particularly for higher levels of cover 
spanning the remainder of life (whole-of-life cover). Despite significant advances in survival 
on ART that many studies report, available studies in South Africa do not focus on relative 
mortality risk which insurers use to adjust HIV-uninfected mortality, nor do they report sufficient 
granularity for insurers to credibly assess relative mortality differences by patient subgroup 
and thereby ensure a fair and sustainable price. Given the limited period of observation of 
survival after ART initiation in South Africa, published studies of mortality at longer durations 
on ART are limited. This is a reflection of ART only having been available in the South African 
public sector since 2004, resulting in limited follow-up at longer durations of ART, and high 
rates of loss to follow-up (LTFU) [51, 52] leading to reduced periods of patient observation. At 
the time of writing, uncertainty around long-term mortality on ART had been a key factor in the 
decisions of life insurers, historically, on whether to offer long-term cover (whole-of-life 
policies) to HIV-infected people at higher cover amounts. However, the South African private 
sector has funded ART since the late 1990s and now has sufficient volumes of patients 
observed at longer durations on ART [53-55].  
 
Two phenomena that insurers may have considered in earlier years of ART rollout include 
early mortality on ART and LTFU. Much higher mortality at early durations of ART has been 
reported in resource-limited settings as compared with developed countries [29, 56]. One 
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study estimated mortality in the first year of ART between 8% to 26% in sub-Saharan Africa 
(SSA), with the majority of deaths occurring in the initial months of ART [56]. In a systematic 
review of early mortality in low- and middle-income countries (LMICs), SSA studies were found 
to have the highest mortality in the first year on ART, at 17% [57], when studies were pooled. 
Estimates of mortality amongst South African male adults in the first 6 months on ART ranged 
from approximately 5% to 40% for baseline CD4 counts greater than 500 and less than 50 
cells/μl, respectively [58]. Female adult mortality in the first 6 months on ART in South Africa 
differed mostly from that of males at baseline CD4 counts less than 50, reaching a peak of 
30% [58]. Independent factors associated with early mortality in many LMICs were low 
baseline CD4 count, male gender, advanced WHO clinical stage, low body mass index, 
anaemia and age greater than 40 years [57]. Notably, over 85% and 40% of adults initiating 
ART have initiated at a CD4 count less than 200 and 100 cells/μl, respectively in South Africa 
[22, 28, 58, 59] and sub-Saharan Africa [60]. However, a study of 44,177 adults starting ART 
between 2002 and 2007 in 8 public sector programmes in South Africa found that patients 
initiated ART at less advanced stages of disease over time and at higher CD4 counts [61]. 
Notably, the median baseline CD4 count increased from 68 to 113 cells/μl from 2002 to 2007 
and the proportion of patients with WHO stage 4 conditions reduced from 50% to 28% [61]. 
Consistent with this trend in baseline characteristics, the same study reported a decline in 12-
month mortality on ART from 9% to 6% over the same period [61].  
 
Another phenomenon commonly occurring in LMICs is that a substantial number of patients 
starting therapy are lost to follow-up (LTFU). In a review covering several SSA countries, 25%-
50% of patients starting ART were LTFU after 2 years [51]. Since high levels of LTFU have 
also been cited in the US and UK [62, 63], this suggests that high levels of LTFU are not 
limited to resource-limited settings. In SSA, it appears that the risks factors for mortality are 
similar to those for LTFU [64] and that patients that are most difficult to follow up may also be 
those with the highest mortality [65]. LTFU can result in potentially significant underestimation 
of the actual mortality levels when based only on passive death information. Notably, mortality 
was estimated to be under-reported by at least 100% when comparing estimates obtained 
from passive monitoring vs. linkage with vital death registries [58]. This is further supported by 
high estimates of cumulative mortality of patients LTFU at 1, 12 and 24 months after their last 
visit: 23%, 31% and 44%, respectively [52]. Another study estimated 12-month LTFU to 
consistently increase per year of enrolment from 1% in 2002 to 13% in 2006 and 12-month 
programme retention declined from 90% to 82% over the same period [61]. Given the potential 
impact on mortality from LTFU periods and that insurers remain on risk in the event of LTFU 
after issuing the insurance policy, insurers may have had concerns about the uncertainty 
around future mortality.  
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1.1.3 Rationale for comparison with Type 2 Diabetes (DM2) 
 
The insurability of HIV-infected people can be given context by comparing their prognosis to 
patients with chronic manageable diseases that are already insurable for high cover amounts 
(sums assured) for the remainder of life (whole-of-life cover). Assessing the relative mortality 
in treated HIV and DM2 using a suitably designed control cohort allows us to identify 
subgroups of HIV-infected lives with insurable levels of relative risk and subgroups with 
relative risk levels that are comparable to that of a chronic condition that was already insurable. 
An application of these comparisons is to the provision of equitable access to financial services 
such as life assurance for HIV-infected people and to ensure that premiums are actuarially 
sound, fair and evidence-based – this comes amidst both an ethical and regulatory 
requirement for customers of life assurers to be treated fairly. An increasing number of HIV-
infected people seek life insurance but, at the time of initiating the research in 2013, many 
were declined insurance at higher cover amounts for the whole of life or found that available 
insurance was limited in scope, required unaffordable premiums or that clinical criteria had to 
be met after taking out the insurance to maintain coverage. The latter contrasted with other 
insurable chronic conditions like DM2 that required medical underwriting only at the time of 
applying for insurance and not continuously thereafter. DM2, a condition characterised by 
raised blood glucose levels, has some medical similarities to HIV: both require lifelong 
treatment, both have laboratory markers of disease control, e.g. viral load and HbA1c from 
which to define patient subgroups with insurable levels of relative mortality, and both pose 
major public health burdens in South Africa [66, 67].  
 
With an increasing prevalence of overweight and obesity [68], concern has risen about a global 
diabetes epidemic and increasing mortality globally [69] and in South Africa [70]. The 
International Diabetes Federation (IDF) estimated that 451 million people (aged 18–99 years) 
had diabetes globally in 2017, expected to increase to 693 million by 2045. The prevalence of 
diabetes is estimated to increase from 8.4% in 2017 to 9.9% in 2045. People with DM2 have 
an increased risk of serious life-threatening health conditions, resulting in increased mortality 
[71]. The IDF estimated that 5 million deaths were attributable to diabetes globally in ages 20–
99, accounting for 9.9% of corresponding all-cause mortality. Further, Africa accounted for the 
largest (74%) proportion of all deaths attributable to diabetes occurring before the age of 60, 
having clear overlap with insurable ages. The global healthcare expenditure on people with 
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diabetes was estimated to be USD 850 billion in 2017. High prevalence of diabetes has 
significant social, financial and developmental implications, especially in LMICs.  
 
DM2 prevalence has been rapidly increasing in South Africa [67], driven by population ageing, 
economic transition and urbanisation associated with changes in diet and obesity. The IDF 
now estimates the number of adults with DM2 in South Africa to be 1.83 million (5.4% 
prevalence) in 2017. South Africa is facing a quadruple burden of disease due to the high 
prevalence of infectious diseases, non-communicable disease, maternal and child mortality, 
and injury-related disorders. As HIV-related mortality reduces, DM2 will become increasingly 
important in South Africa’s burden of disease. 
 
Three main categories of diabetes are recognised: type 1, or juvenile diabetes; type 2, which 
mainly occurs in late adulthood; and gestational diabetes, which occurs during pregnancy. 
This thesis focusses on DM2 as the most prevalent form, accounting for 90%–95% of all 
diabetes cases globally and in Africa [72, 73]. Africa is expected to have the largest percentage 
increase (90%) in adult diabetes numbers by 2030. However, every region is estimated to 
have an increase in numbers well in excess of adult population growth [74].  
 
Several studies in developed countries have identified risk factors for mortality amongst people 
with DM2. Age at diagnosis is an important prognostic factor for mortality [75-77]. Excess 
mortality is estimated to increase with duration of DM2 due to increasing complications [78]. 
Other prognostic factors which are related to the probability of diabetic complications are 
average blood sugar levels (HbA1c); blood pressure; further cardiovascular risk factors like 
smoking, lipids and overweight; proteinuria and retinopathy [79-84]. One of the most important 
prognostic factors is how well blood sugar is adjusted by medical treatment and/or dietary 
measures. HbA1c reflects an average blood sugar level over a period of four to six weeks 
before the test. Recent studies indicate that very strict control of HbA1c is more successful in 
type 1 than in type 2 diabetes [84, 85]. High blood pressure aggravates diabetic vascular 
damage. Studies show that good control of blood pressure significantly improves the 
prognosis for DM2, while mortality increases exponentially with higher blood pressure [86, 87]. 
Proteinuria and retinopathy can be seen as first signs of microvascular damage to the kidneys 
and eyes, where it first becomes visible. Corresponding tissue alterations can be found in 
other organs, like the heart or brain, where it cannot be detected as easily. Thus, both are 
early markers of system-wide diabetic organ damage.  
18 
 
 
DM2 was perceived to be rare or poorly documented in rural Africa, but over the past few 
decades it has emerged as an important non-communicable disease in sub-Saharan Africa 
[72, 88]. However, mortality rates in African DM2 patients have received little attention [89]. A 
search of PubMed and EBSCO updated until 11-02-2019, using the keywords ‘diabetes’, 
‘mortality’ and ‘South Africa’, returned two results each, mostly focussed on type 1 diabetes. 
One of these provides an overview of diabetes in South Africa [90] in 1998 and notes that 
information on DM2 in SSA is limited; it cites three papers dating to the early 1980s. 
Unfortunately, it does not provide estimates of mortality of DM2 patients. A systematic review 
of diabetes in SSA from 1999-2011 reports three studies of mortality in patients with diabetes 
accessing healthcare in the region, two of which were conducted almost 20 years ago [73]. It 
concludes that an evidence base in sub-Saharan Africa is lacking and recommends research 
on mortality in DM2. 
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1.2 Aims and objectives 
 
1.2.1 Aims 
 
This thesis aims to provide a credible basis of evidence to understand the relative mortality 
risk of HIV-infected South African adults starting ART according to both baseline and time-
updated characteristics and to enable insurers to fairly assess the risk and expand the 
insurability of HIV-positive people in South Africa.  
 
1.2.2 Specific objectives 
 
The following objectives are proposed: 
• Assess the relative all-cause mortality risk of South African adults with HIV-1 infection 
initiating ART, using an appropriately designed HIV-uninfected control (comparator) and a 
further benchmark of South African adults initiating therapy for DM2, some of whom are 
already insured.  
• Identify subgroups of HIV-infected South African adults on ART with insurable levels of 
relative risk by considering both baseline and time-updated characteristics. 
 
It is important to note that the purpose of including DM2 is only to provide a broad benchmark 
of relative risk in HIV-infected people compared to that of another chronic condition that was 
already insurable at the time of writing. Further, given the limited published research (see the 
literature review) and data available on the survival of South African adults starting therapy for 
DM2, DM2 is not the focus of this study. 
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1.3 Methods 
 
1.3.1 Study design 
 
A retrospective cohort analysis was undertaken using data from open private medical 
schemes in South Africa administered by Medscheme (Pty) Ltd. The HIV cohort was drawn 
from the Aid for AIDS (AfA) programme, a private sector HIV disease management 
programme (DMP) within Medscheme, which is available to beneficiaries of contracted 
medical schemes in Southern Africa. The control and DM2 (defined below) cohorts were 
drawn from one of the larger medical schemes administered by Medscheme, which has a 
similar demographic and socio-economic profile to the AfA population, and included a large 
percentage of AfA patients in the analysis.  All the above populations are typically employed, 
of higher socio-economic status and have better access to private healthcare than the general 
population. ‘Private sector’ in the title highlights the higher socio-economic status of the study 
population (making it a more suitable proxy for insured populations than the general population 
in South Africa) and the private sector nature of healthcare funders and DMPs. This thesis 
will, however, relate the findings to those of LMICs and high-income country studies. 
 
1.3.2 Cohorts 
 
From the above medical scheme population data, the following cohorts were selected: 
• HIV cohort: HIV-infected South African patients initiating ART that are enrolled on the 
AfA HIV DMP; 
• DM2 cohort: DM2 patients starting therapy for DM2 in a large medical scheme with 
comparable socio-economic profile to the AfA cohort; and 
• Control (comparator) cohort: beneficiaries uninfected with HIV and without DM2 across 
the observation period. The control group users of the medical scheme populations 
(insurance scheme).   
 
More details are provided in section 3. 
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1.3.3 Insurance context for relative mortality risk 
 
Relative risk is defined in general as the ratio of mortality in a given group (e.g. HIV cohort) to 
that in another group (e.g. control cohort). Insurability of chronic conditions is often defined by 
a threshold of relative risk, typically 5 times the mortality of applicants that meet medical 
underwriting requirements (known as standard risks). Therefore, insurance applicants would 
typically be declined insurance if their relative risk exceeds 5 times that of standard risks. The 
insurance industry practice for underwriting (or assessing insurance risk to ensure that pricing 
is commensurate with the risk) medical impairments such as HIV or DM2 is to derive a level 
of relative risk that remains constant across the lifespan of the insurance policy and therefore 
represents a long-term average of the relative risk compared to the control (background 
mortality of standard risks). In order to enable insurers to use the study results to assess 
relative risk from the time of applying for insurance, the study estimates relative risk from a 
given time point on ART over all remaining follow-up. This is not equivalent to relative risk 
calculated during a given time interval of ART where the duration of ART and current age are 
held constant. The ART-CC estimated relative risk in the latter format and correctly points out 
that since relative risk in HIV-infected people starting ART varies with current age and time on 
ART, no single result from their adjusted relative risk ratios applies to a given insurance policy 
[50] and requires further actuarial methods for converting varying relative risk ratios into a level 
relative risk that remains constant across the insurance policy’s term. The novel approach to 
relative risk presented in this thesis better meets the requirements of the insurance industry 
and identifies subgroups of HIV-infected South African adults starting ART with insurable 
levels of relative risk.  
 
1.3.4 Control mortality 
 
Background mortality used by insurers represents people that have been tested HIV negative 
in the recent period prior to applying for insurance. A range of factors were considered in 
designing the control cohort. From the author’s actuarial experience over 13 years in the South 
African life insurance industry undertaking modelling of the demographic impact of HIV and 
AIDS, HIV prevalence observed in people undergoing a test when applying for insurance is 
very low (<1%). Secondly, insured lives have relatively much lower HIV incidence (new 
infection) rates than the general population. Therefore, the study control cohort is selected 
such that they could be assumed to remain HIV-uninfected and without DM2 across the 
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observation period.  This is a strength compared to other studies that compare mortality in 
patients starting ART to that in the general population and those in high-prevalence settings 
that further estimate the HIV-unrelated component of general population all-cause mortality. 
Mathematically, however, HIV-unrelated mortality in the general population is not equivalent 
to the mortality in the HIV-uninfected subgroup. Selecting the HIV, DM2 and control cohorts 
from the same medical scheme population and defining the control to be HIV-uninfected and 
without DM2 across the observation period therefore provides a much stronger comparison 
than using the general population or insured lives as background mortality in relative risk 
estimation. More details are provided in section 3. 
 
1.3.5 Statistical analysis 
 
Relative risk is estimated using a generalized linear model (GLM) assuming a Poisson error 
distribution with log link function [91] and with expected numbers of deaths based on the 
control cohort (person-years of observation (PYO) at risk multiplied by the mortality incidence 
rate in the control cohort) according to age, gender and population group specified as an offset 
[92]. Use of expected deaths as the offset enabled a model of relative risk. The same approach 
to modelling relative risk was followed by the ART-CC [50]. However, to meet insurers’ need 
for constant relative risk estimates across the policy lifetime, relative risk was estimated from 
each 6-month time point on ART over the remaining follow-up (PYO), including both baseline 
and current (time-updated) CD4 and viral load values. In contrast, the ART-CC estimated 
relative risk in defined intervals of ART [50] only including CD4 count and viral load 
measurements at baseline and 6-months after starting ART. The novel approach presented 
in this thesis enables insurers to assess relative risk based on the length of time since starting 
ART when applying for insurance, current CD4 count and viral load and baseline CD4 count. 
More details are provided in section 3. 
 
1.4 Structure of the thesis 
 
Section 2 reviews literature that is relevant to the research objectives. Section 3 provides an 
analysis in the format of a journal paper since the intention is to refine the research into a 
journal paper for publication. Section 4 provides conclusions and identifies areas of further 
research 
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1.5 Ethical considerations 
 
This is a retrospective analysis of data collected for programme management purposes and 
data extracted from the database for this analysis was anonymized and shall remain subject 
to all confidentiality agreements between AfA and UCT. Approval for data collection, analysis 
and research publication was granted by the ethics committee of the University of Cape Town, 
Aid for AIDS Disease Management Programme (Pty) Ltd, Cape Town and AfroCentric Health 
Limited, South Africa. All patients have signed consent for their information to be entered into 
the AfA database. 
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2. Literature review 
 
 
2.1 Overview and objectives 
 
Given the background already covered in section 1 and the vast and varied focus of literature 
that now exists on the epidemiology, pathogenesis and treatment of HIV [1] and the prognosis 
of HIV-infected patients starting ART, the objective of this chapter is to provide a focussed 
review of only the literature that is directly related to the research objectives and context.  
 
Literature is reviewed under three sections on the following inclusion criteria: the insurability 
of HIV-infected South African adults starting ART; the relative mortality risk of HIV-1 infected 
South African adults starting ART specifically, using an HIV-uninfected control (comparator) 
and including patient subgroups defined by baseline and time-updated CD4 count and viral 
load; and comparisons of the relative mortality risk of HIV-infected South African adults starting 
ART (compared with an HIV-uninfected control) and South African adults with DM2 starting 
DM2 therapy (compared with a DM2-negative control). Further, the focus is on HIV and not 
DM2. DM2 is only reviewed broadly in the context of a medical impairment or chronic condition 
that is currently insured. Literature focussing on other settings or without an HIV-uninfected 
control (or mortality instead of relative mortality) is included only where literature in South 
Africa was deemed inadequate and where other literature may have generalisability to the 
study’s context. 
 
2.2 Literature search strategy 
 
The PubMed and EBSCO host databases were searched for relevant articles until 11/02/2019. 
Search terms are provided in each respective section below. While the review is not intended 
to be a systematic review, all references cited in the relevant studies were considered and 
additional studies included where relevant.  
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2.3 Insurability of HIV 
 
Preliminary results of this Masters research have already been presented at the 2014 
International Congress of Actuaries [2]. Further, a search of PubMed using the terms and logic 
(HIV[Title]) OR antiretroviral[Title]) AND insurability[Title]) returned three studies, none of 
which were in South Africa or met the other abovementioned inclusion criteria. Only one of the 
studies assessed the insurability of HIV-infected adults starting ART by estimating relative 
mortality risk using an HIV-uninfected control [3]. This study was conducted by the ART Cohort 
Collaboration (ART-CC). The ART-CC, described in detail elsewhere [4, 5], is an international 
collaboration of HIV cohort studies that combines data on HIV-infected patients who are 
reported to be ART-naïve when they started ART. The ART-CC study, however, has several 
limitations for application in an insurance context which are covered below. 
 
First, the ART-CC defines relative risk during a time interval of ART where the duration of ART 
and current age are held constant. The ART-CC correctly points out that since relative 
mortality risk was found to vary with current age and time on ART, no single result from their 
adjusted relative risk ratios applies to a given insurance policy [3] and requires further actuarial 
methods for converting varying relative risk ratios into the format required by insurers, namely 
a level relative risk that remains constant across the insurance policy’s lifetime.   
 
Second, the HIV and control cohorts are not selected from the same sub-population since the 
control represents HIV-uninfected insured lives and the HIV cohort does not represent insured 
lives in general. While the ART-CC controls for underwriting effects by using ultimate levels of 
insured-lives mortality (which factors out selection bias), material differences in the HIV and 
control cohorts, e.g. transmission group, could not be controlled for. For example, a much 
higher percentage of the HIV cohort was represented by the MSM transmission group (40%) 
than is expected within insured lives, which causes a mismatch in risk profile that cannot be 
controlled for by using insured lives mortality. Since the HIV transmission group is not 
applicable for insured-lives mortality, the HIV and control cohorts could not be matched by 
transmission group to achieve greater comparability.  
 
Third, since the immunological and virological response to ART is represented only via the 
CD4 count and viral load measured at 6 months on ART, the study does not allow direct 
estimation of relative risk at later durations of ART using the current CD4 count and viral load. 
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The study, therefore, does not assist insurers to assess the relative risk of an insurance 
applicant based on the current CD4, viral load and time since starting ART when applying for 
insurance. Further, the study does not assist insurers to understand the effect of the baseline 
(measured at initiation of ART) CD4 count after adjusting for the current CD4 count and viral 
load. These limitations of the ART-CC study become increasingly relevant as HIV-infected 
patients on ART increasingly survive and apply for insurance at longer durations on ART when 
baseline variables may be less prognostic for relative risk than current or time-updated values 
(discussed in detail below and in the subsequent section). Insurers in South Africa have 
already provided the feedback that some HIV-infected applicants on ART no longer have 
access to their baseline or 6-month measurements, which could be due to patients transferring 
between ART programmes with limited portability of the patient’s history [6]. Further, insurers 
may deem it unreasonable for insurance applicants to provide their baseline or 6-month CD4 
count or viral load, potentially measured many years prior to applying for insurance as patients 
survive increasingly longer on ART.  
 
Fourth, and perhaps of even greater concern, is that the ART-CC published this study in 2013, 
after an ART-CC study in 2009 had already shown that when the CD4 count and viral load 
values at 36 months on ART are adjusted for, the CD4 count at baseline and at 6 months had 
insignificant prognostic value for mortality beyond 36 months on ART and, instead, the current 
CD4 count and viral load at 36 months were the most prognostic risk factors for mortality 
beyond 36 months on ART [7]. While the ART-CC reports [3] that the baseline CD4 count and 
viral load were not sufficiently prognostic for relative risk from 6 months on ART onwards after 
adjusting for the corresponding 6-month measurements, it does not report the adjusted relative 
risk ratios and confidence intervals for the effect of baseline CD4 count. The first ART-CC 
study to consider the effect of baseline CD4 count after adjusting for the response to ART [8], 
although focussed on mortality and not relative mortality, reported the effect of the baseline 
CD4 count after adjusting for the 6-month CD4 count and viral load. The first ART-CC study 
was based on only 9,323 patients and 152 deaths (17–32 deaths per baseline CD4 strata), 
which is not considered credible, is as evident from the wide confidence intervals for the 
adjusted hazard ratios for baseline CD4 count. Further, the reported adjusted hazard ratios 
are estimated over all remaining follow-up time after 6 months on ART. If lower baseline CD4 
count, after adjusting for the response to ART, has a significant effect only in the early 
durations of ART, this would only be possible to determine by including time since starting 
ART and interacting this with baseline CD4 count in the model. In the absence of the latter, 
combining all follow-up after 6 months may mask the prognostic effect of a lower baseline CD4 
count in early durations of ART. A more recent ART-CC study [9] assessed the prognostic 
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value of baseline CD4 count for mortality in patients followed for up to 15 years after starting 
ART and found that the baseline CD4 count was significant only in the first 5 years, however; 
the response to ART was not adjusted for.  
 
Fifth, while the baseline CD4 and viral load were not prognostic, after adjusting for the 6-month 
values, advanced HIV clinical stage was prognostic (measured by the U.S. Center for Disease 
Control and Prevention (CDC) classification system stage C: AIDS-defining illnesses). The 
CDC classification system is based on the lowest documented CD4 count and on previously 
diagnosed HIV-related comorbidities. The ART-CC, however, do not report whether the 
prognostic value of CDC stage C changes with increasing time on ART [3].  
 
Sixth, other studies have explored whether baseline CD4 count retains some predictive value 
in the event of ART interruption: The Strategies for Management of ART (SMART) study [10] 
evaluated whether the risks associated with long-term use of ART could be reduced through 
the interrupted use of ART vs. continuous ART (viral suppression strategy). Patients who 
reinitiated continuous ART after episodic interruption experienced rapid virological 
suppression (89.7% with viral load ≤ 400 copies/ml after 6 months), but CD4 counts after 6 
months remained below baseline levels [10]. This suggests that ART interruption may be 
associated with a plummeting reversion of the current CD4 back to baseline levels and, given 
the high proportion of patients in South Africa that initiated ART at CD4 counts below 200, this 
could yield significantly increased mortality. 
 
Seventh, although the ART-CC study [3] is reported to represent patients who were ART-
naïve when they started ART, 8% of patients had a baseline viral load of <500 copies/ml, 
which may suggest some patients were not ART-naïve when starting ART. 
 
One of the gaps in the literature is study of the relative risk of patients starting ART on current 
ART guidelines recommending ART initiation from diagnosis on the basis of which insurers 
can expect to assess the risk of applicants with very high baseline CD4 counts and early 
clinical stage. Historical data are not generalisable to such patients since ART initiation at CD4 
counts ≥350 cells/µl was typically due to advanced clinical stage under the prevailing ART 
guidelines. Such patients can be expected to have a worse prognosis than patients initiating 
without advanced clinical stage [2]. 
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In summary, to the author’s knowledge, no study exists on the insurability of HIV-infected 
South African adults starting ART. Further, no study exists globally on the insurability of HIV-
infected adults starting ART according to both baseline and current (time-updated) CD4 count 
and viral load measured from multiple time points on ART onwards using an HIV-uninfected 
control chosen from the same subpopulation. 
 
2.4 Relative mortality of HIV-1 infected South African adults starting ART: 
comparison with HIV-uninfected mortality as control 
 
The following three PubMed searches, updated until 11-02-2019, yielded 1, 2 and 16 studies, 
respectively. The search terms were iteratively refined by considering the references cited in 
the initial resulting studies until the terms most common and relevant to the research 
objectives were identified. 
• (comparison[Title]) OR compared[Title]) OR uninfected[Title]) OR non-HIV[Title]) OR 
general population[Title]) AND mortality[Title]) AND antiretroviral[Title]) AND South 
Africa[Title]) NOT children[Title]) NOT infants[Title]); and 
• (comparison[Title]) OR prognosis[Title]) OR compared[Title]) OR uninfected[Title]) OR 
non-HIV[Title]) OR general population[Title]) AND mortality[Title]) AND HIV[Title]) AND 
South Africa[Title]) NOT children[Title]) NOT infants[Title]); and 
• (comparison[Title] OR compared[Title]) OR uninfected[Title]) OR non-HIV[Title]) OR 
general population[Title]) AND mortality[Title]) AND antiretroviral[Title]) NOT 
children[Title]) NOT infants[Title]). 
 
To the author’s knowledge, none of the above studies or any others fulfilled the literature 
review inclusion criteria, in particular to estimate the relative risk of HIV-infected South African 
adults starting ART according to both baseline and current (time-updated) CD4 count and viral 
load measured from multiple time points on ART onwards using an HIV-uninfected control 
chosen from the same subpopulation. Several studies identified in the PubMed search are 
however reviewed below to locate the study within existing literature deemed most relevant to 
the research objectives. 
 
The International epidemiological Databases to Evaluate AIDS (IeDEA) collaboration 
estimated standardised mortality ratios (SMRs) that compare mortality rates observed in HIV-
infected patients starting ART with HIV-unrelated background mortality in the general 
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populations of four countries in SSA [11]. The generalisability of this study to the insurance 
context in South Africa is, however, limited by their reporting on only the first two years of ART, 
having small patient numbers (5,282) from South African treatment programmes, not 
considering the response to ART (time-updated CD4 count and viral loads), and not 
considering the interaction of baseline and time-updated characteristics. Further, IeDEA uses 
HIV-unrelated mortality as the control, which mathematically, is not equivalent to the mortality 
in the HIV-uninfected sub-group of a general population. To be generalisable for insurance 
purposes, the control needs to represent a population that is HIV-uninfected and is largely 
expected to remain so in the future. This is because insurers require relative risk estimates 
that can be applied to the mortality of insurance applicants assessed as standard risks by 
medical underwriting which includes being tested HIV negative at the time of applying for 
insurance. While IeDEA is correct to adjust general population all-cause mortality by removing 
HIV-related mortality to avoid bias [12], given the high HIV prevalence setting, a mismatch 
remains with the mortality of the HIV-uninfected subpopulation. Further, IeDEA’s estimates of 
HIV-unrelated mortality are likely to be inaccurate when applied to the populations from which 
the HIV-infected cohorts originated and, therefore, errors in the calculation of the expected 
number of deaths may not be apparent in confidence intervals of SMRs [13].  
 
Certain findings have relevance to the research objectives. The effect of baseline CD4 count 
on SMRs was found to depend on the time period after starting ART and an interaction 
between baseline CD4 count and time on ART was included in IeDEA’s model. Overall, 
mortality during the first 2 years of ART was more than 18 times higher than the reported 
general population HIV-unrelated mortality due to only 14% of patients initiating ART above a 
CD4 count of 200 cells/µl and 82% starting with advanced clinical stage (WHO stage III or 
stage IV). However, large variability between subgroups was reported over time on ART: for 
patients with very low baseline CD4 counts (<50 cells/µl) and advanced baseline clinical stage 
(WHO stage III or stage IV) mortality was 300 times in the first 3 months of ART whereas in 
year 2 of ART patients who started with baseline CD4 counts ≥200 cells/µl and less advanced 
baseline clinical stage (WHO stage I or stage II) had comparable mortality to HIV-unrelated 
levels (SMR 1.14 [95% CI 0.47;2.77]). 
 
In a further study, the ART-CC compared mortality rates observed in 13 cohort studies of 
29,935 HIV-1-infected patients starting ART with those observed in the corresponding general 
populations of 9 industrialised countries. SMRs were calculated from 6 months after starting 
ART (thus allowing for the response to ART), by 6-month CD4 count and viral load, HIV 
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transmission risk group, and clinical CDC baseline stage. An SMR of 1.33 [95% CI 1.00;1.75] 
was reported in follow-up after 6 months on ART in patients from the heterosexual 
transmission risk group, with clinical CDC baseline stage A/B, attaining 6-month CD4 counts 
≥350 cells/µl and viral loads ≤500 copies/ml. The study concludes that the mortality of HIV-
infected patients starting ART in industrialized countries and surviving the first 6 months 
continues to be higher than in the general population, but for many such patients mortality is 
comparable with that of patients having other chronic conditions. Like the ART-CC’s more 
recent study [3], this study has limited generalisability to an insurance context, given the 
absence of current CD4 count and viral load measured at multiple time points on ART and 
using a suitably matched HIV-uninfected control cohort. 
 
Some studies [14, 15] assess SMRs relative to general population during time periods when 
the CD4 count remained at a particular level and find that mortality during periods when the 
CD4 count remained ≥500 cells/µl may reach the level of the general population if the CD4 
count is maintained over a long enough period. However, such methodologies are not 
generalisable to insurance since people are insured based on their past and current risk 
characteristics at the time of applying for insurance and, therefore, the assumption of a 
constant CD4 count ≥500 cells/µl in future cannot be made by the insurer with available 
information.  
 
Several studies in resource-rich countries report that mortality in HIV-infected people on ART 
remains higher than in the general population [16-18] even among individuals who experience 
a good initial response to ART [19] but that the excess mortality of certain subgroups of 
patients is moderate [16, 18-22]. Other studies identified subgroups of patients on ART with 
similar mortality to the general population [15, 23, 24]. Studies [25, 26] that were deemed to 
lack credibility in-patient volumes are not included. 
 
One study sought to compare mortality rates in well-controlled (virologically suppressed) HIV-
infected adults in the SMART and ESPRIT clinical trials with the general population [23]. Three 
sub-analyses estimated SMRs by: (a) using follow-up where at some point in the past 6 
months both the viral load was suppressed and the CD4 count was ≥ 350 cells/µl, (b) 
restricting follow-up to periods where both the viral load was suppressed and the CD4 count 
was ≥ 350 cells/µl according to the most recently measured values, and (c) expanding follow-
up to include exposure where both the viral load was suppressed and the CD4 count was ≥ 
350 cells/µl at any time since enrolment. None of these analyses enable an insurer to assess 
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the relative risk over long future periods based on the current CD4 count and viral load nearest 
to the time of applying for insurance or to understand the interaction of baseline and current 
measurements and time since starting ART at policy application. 
 
Many South African studies provide valuable insights into the prognostic factors for survival, 
often focussing on mortality and not relative mortality on ART and, therefore, do not meet the 
other inclusion criteria. For example, one study analysed 14,932 patients initiating ART at a 
large public sector clinic in South Africa [27]. A key finding of the paper is that while the current 
(time-updated) CD4 count is the dominant predictor of mortality, the effect is modified by viral 
load and the time elapsed since starting ART. Other studies also suggest that the current 
(time-updated) CD4 count is the dominant driver of a patient’s risk of mortality on ART [4, 8, 
28-30]. The cumulative person-time at low CD4 counts (e.g. <100 cells/µl) has also been 
reported to be prognostic of mortality [31], which suggests that baseline CD4 count alone may 
not be sufficient to explain mortality over time [32-34]. Further, it is reported that the impact of 
current viral load, although more consistent over time on ART than current CD4 count, is not 
stable over time on ART and appears more dominant at early durations on ART in patients 
with higher CD4 counts, when the overall risk of mortality is lower and therefore virological 
suppression plays a more dominant role. Early and consistent virological suppression is 
therefore critical to maintaining optimal outcomes on ART [2, 11]. These results, while 
comparable with an analysis of mortality in sub-Saharan-African cohorts [35], do not include 
baseline characteristics because of concerns over multi-collinearity with current values. The 
latter concern has, however, been overcome by methods used elsewhere [3, 7]. 
 
In summary, to the author’s knowledge, no study has estimated relative risk in HIV-infected 
adults starting ART according to both baseline and current (time-updated) CD4 count and viral 
load measured from multiple time points on ART onwards using an HIV-uninfected control 
chosen from the same subpopulation. 
 
2.5 Comparison of relative mortality in treated HIV-infection and type 2 
diabetes 
 
To the author’s knowledge, no study exists that compares relative risk in South African HIV-
infected adults starting ART with that in South African adults with DM2 starting DM2 therapy 
using an HIV uninfected and DM2 negative control. Studies in other settings have suggested 
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that all-cause mortality in many patients successfully treated with ART are comparable with 
other chronic conditions requiring lifelong treatment, such as diabetes [20]. Relative risk in 
patients with DM2 depends on age at diagnosis, reflecting higher general population mortality 
in older ages and, thus, smaller relative risk in the case of older ages compared to younger 
subgroups. Mortality ratios resulting from different studies in developed countries range from 
3 times general population mortality for ages below 50 to 1.5–2 at ages 50–65 and 1.3–1.7- 
at ages above 65 [36, 37].  
 
A systematic review of DM2 in sub-Saharan Africa 1999–2011 reported three studies of 
mortality in patients with diabetes accessing healthcare in the region [38]; two of the studies 
were several decades old and may not be applicable. One of the three reported 5-year 
mortality at 19% amongst DM2 patients. The other two focus on type 1 diabetes. These studies 
reported high mortality levels, with 5-year mortality estimates ranging from 4%–57%. The 
study concludes that an evidence base in sub-Saharan Africa is lacking and recommends that 
further studies exploring the specific causes of mortality in DM2 patients should be 
undertaken. 
 
 
2.6 Conclusions 
 
To the author’s knowledge, no study has estimated the insurability of and relative risk in HIV-
infected adults starting ART according to both baseline and current (time-updated) CD4 count 
and viral load measured from multiple time points on ART onwards using an HIV-uninfected 
control chosen from the same sub-population. As mentioned by the ART-CC [3], research on 
the insurability of HIV-infected South African adults starting ART is urgently needed, 
specifically using an HIV-uninfected control (comparator) and including patient subgroups 
defined by baseline and time-updated CD4 count and viral load. 
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3 Insurability of South African adults with HIV-1 infection starting 
antiretroviral therapy 
 
3.1 Overview 
 
The intention of this chapter is to present an analysis of insurability of South African adults 
with HIV-1 infection starting ART. The structure is consistent with publication in an academic 
journal. Certain content in the journal paper below may have duplication with the broader 
thesis since the intention is to publish relevant sections of thesis in a self-standing journal 
paper. The focus of this chapter is both to replicate the ART-CC [1] methodology on South 
African cohort data and to present a novel methodology to address some limitations of the 
ART-CC study. A more detailed discussion of the limitations of the ART-CC studies is included 
in the literature review (chapter 2). The preliminary findings received a best-paper award at 
the International Congress of Actuaries, Washington (2014) and have subsequently been 
widely presented to insurers in South Africa, Europe and North America, already influencing 
insurers that were still declining insurance for HIV-positive people to accept a majority of the 
applications.  
 
3.2 Abstract 
 
Objective: To determine whether there are subgroups of HIV-positive people on ART in South 
Africa who are insurable. 
Design: A retrospective cohort study 
Methods: We assess relative all-cause mortality risk in South African adults with HIV-1 
infection initiating ART between 1998–2013 using an HIV-uninfected control cohort 
(comparator) and a further benchmark against South African adults with DM2 initiating DM2 
therapy. Relative risk is estimated by both baseline and current (time-updated) characteristics 
and subgroups are identified with insurable levels of relative risk as well as subgroups that 
attain HIV-uninfected levels of mortality. We used Poisson models for mortality, with the 
expected number of deaths based on mortality derived from the control according to age, 
gender and population group as an offset.  
Results: In the HIV cohort, 8,920 deaths were recorded in 77,325 patients followed for 
315,341 person years (median follow-up of 3.23 years [IQR 2.04;5.30]). In the DM2 cohort, 
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7970 deaths were recorded in 67,705 patients starting antihyperglycaemic therapy (“DM2 
therapy”) followed for 365,547 person years (median follow-up of 6.20 years [IQR 3.85;9.53]). 
In the control, 24,838 deaths were recorded in 512,940 patients followed for 3,276,501 person 
years. In the overall HIV cohort, 90% of patients at risk from all time points 6 months or later 
since ART initiation had relative risk within the insurance industry threshold (<5) and within 
patients attaining current CD4 counts of 200+ cells/µl and suppressed viral loads (≤400 
copies/ml) at 6 months on ART or later, 100% of patients at risk had relative risk well below 
the insurance industry threshold. 90% of patients at risk from 1 year of ART onwards had a 
lower or comparable relative risk to the DM2 cohort. Baseline CD4 count was only prognostic 
for relative risk within the first three years of ART after adjusting for the immunological and 
virological response to ART. Patients attaining a current CD4 count of 200+ cells/µl and a 
suppressed viral load (≤400 copies/ml) had the lowest relative risk, reducing with time on ART 
and, for the vast majority, approaching 1 after 3 years on ART, approaching HIV uninfected 
mortality levels. The immunological and virological response to ART between this study and 
the ART-CC study was similar, however, the level of relative risk and the effect of current age 
on relative risk was modified by population group. 
Conclusions: The vast majority of this cohort of South African HIV-infected adults starting 
ART have both insurable levels of relative risk and comparable relative risk to DM2 when 
measured from multiple time points on ART by baseline and current (time-updated) 
characteristics. The only subgroup with relative risk exceeding the insurance industry 
threshold were patients with current CD4 counts ˂200 cells/µl and unsuppressed viral loads 
(˃400 copies/ml). Mortality in the vast majority of this cohort that attained CD4 counts ≥200 
cells/µl and suppressed viral loads (≤400 copies/ml) at 3 years of ART or later approached 
HIV-uninfected levels of mortality. 
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3.3 Introduction 
 
The scale-up of combination antiretroviral therapy (ART), one of the greatest pharmacological 
interventions in human history, has substantially improved the prognosis in HIV-infected 
people in high- and low-income settings alike [2-17] and reduced adult HIV-related deaths in 
South Africa by around 70% between the peak in 2005 and 2019 [18]. It is, however, unclear 
from published studies in South Africa and globally which subgroups of HIV-infected adults, 
defined by both baseline and current (time-updated) characteristics, may achieve HIV-
uninfected levels of mortality and which subgroups have relative mortality that is within the 
insurance industry’s threshold for insurability. Relative mortality estimates are important in 
insurance since insurability is measured by relative mortality, not absolute mortality or other 
measurements such as life expectancy [11].  
 
HIV-infected people are increasingly surviving with longer ART durations. Therefore, there is 
a need for patients, healthcare practitioners, ART programmes, modellers, insurers and 
policymakers to understand the prognosis when measured from later durations on ART based 
on current characteristics. However, most South African ART survival studies are based on 
baseline characteristics, have short follow-up times, low patient volumes and lack HIV-
uninfected controls selected from the same subpopulation for estimating relative mortality. At 
the time of initiating this research in 2013/2014, some insurers were declining HIV-infected 
South Africans applying for higher cover amounts spanning the whole of life. Further, other 
chronic conditions such as Type 2 Diabetes (DM2) had already been insurable for many years 
in South Africa and studies in high-income settings suggest a comparable level of relative 
mortality to DM2 [19-24]. At the same time, the ART Cohort Collaboration (ART-CC) assessed 
the insurability of HIV-infected people starting ART in Europe [1] and issued an urgent call for 
a corresponding study in South Africa. This study responds to this call and, to the author’s 
knowledge, is the first study outside of Europe to assess the insurability of HIV-infected adults 
starting ART by assessing the relative mortality of South African HIV-infected adults initiating 
ART using an HIV-uninfected control (comparator) chosen from the same subpopulation, 
measured from multiple time points on ART using both baseline and current characteristics, 
long follow-up times, significant patient volumes and accurate mortality ascertainment. The 
study identifies patient subgroups with insurable levels of relative risk as well as subgroups 
that attain HIV-uninfected levels of all-cause mortality and is fundamental for evaluating ART 
programmes and for informing evidence-based insurance decisions that are actuarially sound 
and treat insurance customers fairly.  
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3.4 Methods 
 
3.4.1 Study design 
 
A retrospective cohort analysis was undertaken using data from open private medical 
schemes in South Africa administered by Medscheme (Pty) Ltd. The HIV cohort was drawn 
from the Aid for AIDS (AfA) programme, a private sector HIV disease management 
programme (DMP) within Medscheme and available to beneficiaries of contracted medical 
schemes in Southern Africa. The control and DM2 cohorts were drawn from one of the larger 
medical schemes administered by Medscheme, which has a similar demographic and socio-
economic profile to the AfA population and constituted a large percentage of AfA patients 
included in the analysis. All the above populations are typically employed, of higher socio-
economic status and have better access to private healthcare than the general population. 
‘Private sector’ in the title highlights the higher socio-economic status of the study population 
(making it a more suitable proxy for insured populations than the general population in South 
Africa) and the private sector nature of the healthcare funders and DMPs. The paper will, 
however, relate the findings to those of low- and middle- income countries (LMICs) and high-
income country (HIC) studies. 
 
3.4.2 Data 
 
Within the Medscheme management system, demographic data – gender, population group, 
date of birth and South African national identity number (RSAID)), drug dispensing claims, 
laboratory claims, and scheme dates (join, termination and reasons) – were stored. Within the 
AfA management system, demographic data (including additional RSAID), laboratory test 
results (including CD4 count and viral load), and ART authorisation and context were stored 
and made available to AfA clinical staff; the context included pre-exposure prophylaxis (PrEP), 
post-exposure prophylaxis (PEP), and ongoing ART and prevention of mother-to-child 
transmission (PMTCT). AfA clinical staff were responsible for providing guidance in terms of 
protocols, authorised ART reimbursement in accordance with these protocols (e.g. 
prophylaxis of opportunistic infections, infant formula feeding, and some specialised 
investigations), as well as online training for medical professionals and telephonic counselling 
of patients when requested. Before 2002, triple therapy or combination ART was not available 
to all members due to the high cost of ART. Some patients privately purchased a third drug 
when only two drugs were covered by the medical schemes. Information on third drugs was 
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not necessarily available within the electronic health records; however, from 2002 combination 
ART was universally available without co-payment across all schemes. 
 
3.4.3 HIV cohort guidelines  
 
A public sector approach has been promoted in the private and public sector programmes 
alike in South Africa, given the resource constraints. AfA established and maintained HIV 
clinical management guidelines over time and these guidelines were closely aligned with WHO 
guidelines for LMIC settings and South African national guidelines [25]. Aspects that more 
closely resembled HIC guidelines [26-29] included initiating ART at higher baseline CD4 
counts and more flexibility in terms of the regimen prescribed. AfA promoted these guidelines 
with the healthcare professionals registered with AfA and enrolled these professionals in 
ongoing in-house e-learning programmes. New doctors were required to undergo specific 
online training before being eligible to enrol patients with AfA.  
 
The recommended initial regimen was a combination of two nucleoside reverse transcriptase 
inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI). Efavirenz 
(EFV) containing regimens have become increasingly common as nevirapine (NVP) 
containing regimens were no longer preferred in women of child-bearing age and were not 
prescribed for patients on rifampicin for tuberculosis. Regimens with ritonavir-boosted 
lopinavir were the preferred second-line therapy in patients failing first-line therapy. Third-line 
or salvage regimens, containing either darunavir/ritonavir, tipranavir/ritonavir, raltegravir, or 
etravirine have been available since 2007 and the genotype antiretroviral resistance test 
(GART) is used to identify the preferred regimen and confirm failure. 
 
Reimbursement of claims related to HIV-care without co-payment was subject to authorisation 
by AfA clinical staff – 5 CD4 count and viral load investigations per year and 2 healthcare 
professional visits per year for HIV-care, irrespective of funds available, were covered for 
patients registered with AfA. Decisions to start/alter regimens or HIV-related medications (e.g., 
antibiotics) or undergo GART were discussed with AfA clinical staff before authorisation and 
more complex decisions were referred to weekly expert meetings.  
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3.4.4 Definition of cohorts and patient eligibility 
 
The original data for inclusion in the study included the period 1998 to 2013. We then identified 
adults 19 years and older in each of the following three cohorts: 
 
• The HIV cohort consisted of persons who were likely to be HIV positive (either claimed for 
ART, joined AfA, or claimed for either a viral load or CD4 count test) and were then 
dispensed antiretrovirals (ARVs) within the AfA programme; 
• The DM2 cohort consisted of patients who were likely to have DM2 (claimed for anti-
diabetic therapy, registered with the Medscheme DM2 programme, or claimed for HbA1c 
and were then dispensed antihyperglycemic medication; and 
• The Control cohort (also known as a comparator) consisted of persons who were assumed 
to be HIV uninfected and to not have DM2 across the observation period. This assumption 
was made by using the complete medical scheme claims history to identify persons with 
no history of claims for CD4 count tests, viral load tests or any ART medication claims. 
The control was selected from one of the larger schemes which had contracted AfA to 
oversee HIV-related care and Medscheme to oversee all other aspects of care. As 
mentioned, a large proportion of the HIV cohort belonged to the same medical scheme as 
the control. 
 
We excluded pregnant women as they are initiated on ART at higher average CD4 counts 
and have variable CD4 counts compared to the general population [30]. Patients with a 
baseline viral load of ≤400 copies/ml were excluded since the study aimed to assess 
relative risk in ART-naïve patients and a suppressed baseline viral load may indicate prior 
ART exposure. ≤400 copies/ml was used as the lower limit of viral detection in the analyses 
to overcome the heterogeneity of the assays’ detection levels [31]. Other exclusion criteria 
are covered in Appendix A.  
 
3.4.5 Loss to follow-up and mortality ascertainment 
 
Under-reporting of mortality and over-reporting of loss to follow-up will be corrected for by 
linking to the national death registry since, as is widely published, linkages with vital registries 
resulted in a substantial upward revision of all mortality estimates, particularly during the early 
months after initiation of ART [32]. Within South Africa, the national vital registration allows for 
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mortality rates to be accurately determined by linking RSAID to the death registry [33]. Scheme 
beneficiaries were required to submit an RSAID number, but occasionally this was not 
captured for beneficiaries of the main member. RSAID numbers were captured for 98% of AfA 
members. Reported mortality rates within cohort studies from many LMIC have been shown 
to be inaccurate as “missing” patients, who have not returned for clinic visits and subsequently 
died, are usually misclassified as LTFU [11, 34-36].  
 
Within the HIV cohort, patients were deemed to be to be loss to follow-up (LTFU) when ART 
medication had not been claimed for six consecutive months or more. Various definitions of 
LTFU have been described in the literature but 6 months remains the most pragmatic and 
commonly used definition [37, 38]. With the DM2 and control cohorts, patients were not 
deemed to be LTFU; the impact of LTFU can be ignored as insurers accept the risk based on 
the risk profile of the customer at the time of applying for insurance, regardless of future LTFU. 
If LTFU occurs after taking out the insurance policy, the insurer remains on risk and therefore 
the study made no adjustments for LTFU to reflect the associated changes in relative risk. 
 
3.5 Variables 
 
The baseline and current characteristics are important determinants in the HIV cohort and 
included age, CD4 count, viral load ART, and regimen. Baseline clinical stage was not 
available at the time of this analysis but is commonly requested. Importantly, the baseline for 
CD4 count and viral load were defined as the most recent result within the twelve-month period 
before starting ART. For current CD4 count or viral load, which AfA recommended be repeated 
every 6-12 months, we carried forward and backward any CD4 count or viral load result for up 
to 12 months where no other tests were available within a two-year interval, or where available, 
until the mid-point between the subsequent and previous test respectively. The midpoint 
method presents a simple option to reduce bias in time-updated CD4 count analysis, 
particularly at low CD4 cell counts and rapidly increasing counts after ART initiation [39]. The 
current regimen was determined from dispensing or authorization data and carried-forward for 
this analysis. Unlike in Europe where insurance pricing cannot use gender, it is possible in 
South Africa and was therefore considered for applicability in insurance and generalisability to 
other settings and cohorts. 
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3.5.1 Statistical methods 
 
We used generalized linear models (GLM) assuming a Poisson error distribution with log link 
function [40] and with expected numbers of deaths based on the control cohort (person-years 
of observation (PYO) at risk multiplied by the mortality incidence rate in the control cohort) 
according to age, gender and population group specified as an offset in the Poisson GLM [41]. 
Use of the offset enabled a model of relative risk. The same approach to modelling relative 
risk was followed by the ART-CC [1]. However, to meet insurers need for constant relative risk 
estimates across the policy lifetime, relative risk was estimated from each 6-month time point 
on ART over the remaining follow-up (PYO) whereas the ART-CC estimated relative risk in 
defined intervals of ART [1]. Since we wished to model time since starting ART explicitly, we 
did not allow for it in the offset. Baseline variables considered for inclusion were gender, 
population group, year of ART initiation, age at start of ART, baseline regimen and baseline 
CD4 count and viral load (defined above and categorised in Table 1). We additionally 
considered for inclusion in the model variables that varied over time: time since starting ART, 
current (time-updated) CD4 count and viral load (defined above), current age and current 
regimen (defined above). Time since starting ART was measured from 6 months on ART on 
onwards, similarly to the ART-CC [1]. 
 
Factors influencing the selection of variables in the intermediate and final models were multi-
disciplinary and included the applicability of the results in an insurance pricing context; 
generalisability of the results to other cohort studies and settings; conventional statistical 
methods; actuarial and medical insurance domain knowledge; and modern data science 
(statistical learning) techniques. Initially, all variables were included in the model and 
conventional statistical methods were followed including checking p-value significance (p ˂ 
0.05 and also ˂ 0.01) as well checks for overlapping confidence intervals of the exponentiated 
model coefficients (representing adjusted relative risk ratios) and whether they spanned the 
value 1. 95% confidence intervals (CI) for exponentiated coefficients (adjusted relative risk 
ratios) in the final model were bootstrapped by sampling from the total numbers of patients 
with replacement from the full dataset. P-values and CI for adjusted relative risk ratios from 
intermediate models used their robust standard errors to control for mild violation of the 
distribution assumption that the variance equals the mean and the delta method given the 
transformation of model coefficients [42]. Model selection was initially performed on all variable 
combinations excluding interactions and identified models with lower Akaike Information 
Criterion (AIC) [43], specifically the version corrected for smaller sample sizes (AICc) [44-46], 
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as a measure of the relative quality of models differing according to variables included in the 
model considering the trade-off between the goodness of fit and simplicity. AICc was further 
assessed for selected two-way interactions identified through a combination of domain 
knowledge, literature review and a cross-validated penalized Poisson glm regression 
(implemented as glmnet in R) [47] which was used to identify potentially significant two-way 
interactions. The latter approach was selected given its efficiency in assessing all two-way 
interactions, interpretability of model coefficients, ability to relate HIV and expected deaths via 
an offset and its penalty to the Poisson GLM model for having too many variables. The LASSO 
form of glmnet was used which shrinks coefficients to zero that do not improve model 
performance, a process also known as regularization [47].  
 
The top 50 most influential model parameters, including two-way interactions, were identified. 
A subset of models, some including two-way interactions, were identified with the lowest AICc. 
However, AICc does not identify each model’s ability to predict relative risk in a testing 
(holdout) sample of data that was excluded when fitting (training) each model. The concept of 
minimising the model’s prediction error measured on the testing data as opposed to the 
training data, is widely recognised in modern data science [47] as a means to avoid overfitting. 
The performance of the above subset of models was further assessed by fitting the model on 
a randomly selected 80% sample and testing the model’s ability to predict the actual deaths 
observed in the 20% testing data. Models were identified with the lowest Poisson deviance 
calculated on the testing data as a measure of the goodness of fit. The deviance is the 
generalization of the sum of squares in regular multiple regression and measures the 
discrepancy between the fitted values and the data. AIC is equal to the deviance plus twice 
the number of parameters in the model. This approach allowed models to be compared by 
their AICc from the training data and the deviance on the testing data, highlighting the marginal 
improvement in performance from including interactions. Actual relative risk (and confidence 
intervals) observed in patient subgroups of the testing data were also compared with the 
corresponding predicted relative risk in the testing data.  
 
Finally, while population group is inappropriate for use in an insurance context, it is considered 
meaningful to report when generalising the findings to other settings given the differences in 
background mortality. Use of baseline regimen and year of ART initiation may be difficult to 
justify to customers, often relating to many years before the insurance application and may 
also not reflect future regimens and levels of treatment and care. The first 6 months of follow-
up was excluded when deriving relative risk estimates from 6 months onwards to avoid high 
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correlation between the baseline and time-updated variables. Missing baseline and current 
CD4s and viral loads were not imputed. To increase the comparability of the HIV and control 
cohorts, a variable indicating one of two medical scheme groups was included in the model, 
allowing the HIV and control cohorts to be compared within the same medical schemes (i.e. 
control for medical scheme) since the control cohort was extracted from one large medical 
scheme. RStudio version 1.0.143 – © 2009-2016, PowerBI Desktop and Microsoft Excel 2016 
were used to perform the analyses. 
 
3.5.2 Sensitivity analyses 
 
To assess differences in model performance that may be attributable to the impact of 
overdispersion or correlated, repeated observations on the default GLM, a GLM with 
Quasipoisson family and a generalised linear mixed effects model (GLMM) with random effect 
on the patient identifier were compared to the default GLM. 
 
3.5.3 Ethics 
 
This is a retrospective analysis of data collected for programme management purposes and 
data extracted from the database for this analysis was anonymized. Approval for data 
collection, analysis and research publication was granted by the ethics committee of the 
University of Cape Town, Aid for AIDS Disease Management Programme (Pty) Ltd, Cape 
Town and AfroCentric Health Limited, South Africa. 
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3.6 Results 
 
3.6.1 Cohort profiles 
 
Patient characteristics for the various cohorts (HIV, DM2 and control) are shown in Table 1. 
Analysis of the HIV cohort was based on 77,325 patients who started ART between January 
2000 and March 2013 (see Appendix A for eligibility criteria). Following ART initiation, patients 
were followed for 315,341 person-years of observation (PYO) – median follow-up of 3.23 years 
[IQR 2.04;5.30] – in which 8,920 deaths occurred (overall crude mortality incidence (CMI) 
28.29 deaths per 1000 PYO [95% CI 27.71 to 28.88]). Analysis of the DM2 cohort was based 
on 67,705 patients who started antihyperglycaemic therapy (hereafter ‘DM2 therapy’) between 
January 2000 and March 2013. Following initiation of DM2 therapy, patients were followed for 
365,547 PYO (median follow-up of 6.20 years [IQR 3.85;9.53]), in which 7970 deaths occurred 
(overall CMI 21.80 deaths per 1000 PYO [95% CI 21.34;22.29]). Analysis of the control cohort 
was based on 512,940 patients followed for 3,276,501 PYO (median follow-up of 7.24 years 
[IQR 4.50;11.24]), in which 24,838 deaths occurred (overall CMI 7.58 deaths per 1000 PYO 
[95% CI 7.49;7.68]). A higher proportion of patients in the HIV cohort were black (96%) and 
female (64%) compared to approximately 62% (black) and 51% (female) in the DM2 and 
control cohorts. Patients in the HIV cohort initiated ART at a younger median age of 38 [IQR 
33;45] compared to DM2 patients that initiated DM2 therapy at a median age of 48 [IQR 40;56].  
 
Combining all years at which ART was initiated, patients in the HIV cohort initiated ART at a 
median (baseline) CD4 count of 159 cells/µl [IQR 73;241] which consistently increased, 
reaching the typical lower limit of CD4 count in HIV uninfected people (500 cells/µl) after 5 
years on ART (Figure 1). After 12 months of ART, 77% of patients were virologically 
suppressed (viral load ≤ 400 copies/ml), increasing asymptotically to 80% after 10 years on 
ART. These trends manifest in reducing CMI with increasing duration on ART: CMI decreased 
significantly from 81.45 deaths per 1000 PYO [95% CI 78.60;84.38] in the first 6 months of 
ART to 29.7 deaths per 1000 PYO [95% CI 27.73;1.28] during months 6–12, followed by 
relatively smaller reductions thereafter. CMI estimates remained credible as seen by the 
narrow confidence intervals up to 10 years on ART (Appendix D). Within the first 6 months of 
ART, 21% of patients attained both a CD4 count above 200 cells/µl and a suppressed viral 
load, increasing to 49% in months 6–12, 68% in years 1–2 and 80% after 10 years on ART 
(Figure 2). This consistently large subgroup with optimal outcomes on ART manifests in 
significant reductions in CMI overall (Appendix D).  
51 
 
 
A significant differential in CMI is observed in the first year of ART across baseline CD4 count 
strata; however, the differential wanes with increasing time on ART, becoming negligible after 
3 years (Appendix E). Further, lower baseline CD4 strata required longer durations on ART 
compared to higher baseline CD4 count strata to achieve similarly high median CD4 counts 
(Appendix F). The percentage of patients attaining a CD4 count over 200 cells/µl and a 
suppressed viral load over time increased with increasing baseline CD4 count, with the 
exception of baseline count ≥350 cells/µl (Appendix G). Regardless of baseline CD4 count 
strata, within the first 3 years on ART, an increasing percentage of patients attained a CD4 
count over 200 cells/µl and a suppressed viral load which manifests in a waning effect of 
baseline CD4 count on CMI (Appendix E). The reduction in the differential in CMI by baseline 
CD4 count is less pronounced after 3 years on ART (Appendix E). With the exception of 
baseline CD4 count ≥350 cells/µl, the percentage of patients attaining a CD4 count over 200 
cells/µl and a suppressed viral load after 3 years on ART converged across baseline CD4 
count strata (Appendix G) and likely explains the convergence of CMI by baseline CD4 count 
after 3 years on ART where time-updated characteristics are more prognostic as described 
below.  
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 Table 1: Patient characteristics of the HIV (77 325 patients), DM2 (67 705 patients) and control (512 940 patients) cohorts at entry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Age at entry for the HIV, DM2 and control cohorts is defined respectively as the age at ART initiation, age at DM2 therapy initiation and age at joining the medical scheme 
** Year of entry for the HIV, DM2 and control cohorts is defined respectively as the year of ART initiation, the year that DM2 therapy was initiated and the year of joining the 
medical scheme
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Figure 1: Median CD4 count and percentage of patients virologically suppressed (≤400 copies/ml) by 
duration since ART initiation 
 
 
Figure 2: Progression in time-updated CD4 count and viral load by duration of ART 
 
  
54 
 
3.6.2 Relative mortality risk 
 
Overall, a crude relative risk of 4.06 [95% CI 3.98;4.14] and 2.01 [95% CI 1.74;2.31] was 
observed in the HIV and DM2 cohorts, respectively, relative to the control. This section 
describes modelled relative risk estimates measured from a given time point on (or duration 
since starting) ART across the remaining future follow-up (or PYO) per patient and therefore 
representing a longer-term average of the relative risk measured from a given time point on 
ART. This format ensures applicability in an insurance context where relative risk estimates 
used by insurers are averaged over the entire future period of insurance cover. To increase 
the generalisability of the overall findings to other cohorts and published literature, section 
3.5.3 describes further analysis replicating the ART-CC methodology that estimated relative 
risk within defined time intervals of ART. Results from the final relative risk model are 
discussed below, followed by intermediate results leading to the final model selection and, 
finally, a description of the control. 
 
Figure 3 shows relative risk estimated from the final model by time since starting ART, baseline 
CD4 count, current CD4 count, and viral load. Values for all other variables were fixed at the 
reference group level (current age 19–39, female, population group black, baseline viral load 
5log–6log copies/ml and the same medical scheme from which the control was derived). 
Modelled relative risk for a given patient is obtained by multiplying the adjusted relative risk 
ratios corresponding to their characteristics (Appendix I shows crude and adjusted relative risk 
ratios). Each of the four graphs represents a patient subgroup defined by a unique combination 
of current CD4 count (<200 or 200+ cells/µl) and current viral load (≤400 or 400+ copies/ml) 
measured at the given time point on ART, which enables insurers to match relative risk results 
to the insurance applicant’s current duration on ART, CD4 count and viral load. 
 
Figure 3 shows that relative risk was lowest in patients attaining a current CD4 count of 200+ 
cells/µl and a suppressed viral load (≤400 copies/ml) and reduced with time on ART, 
converging with the control cohort (relative risk = 1) after 3 years on ART and therefore tending 
to mortality levels in HIV-uninfected people matched by age, gender, population group and 
medical scheme. Further, within this subgroup, relative risk increased with reducing baseline 
CD4 count but only within the initial 3 years on ART. After controlling for the response to ART 
(current CD4 count 200+ cells/µl and a current viral load ≤400 copies/ml and fixing other 
variables at their reference group values), the effect of baseline CD4 count on relative risk 
waned with increasing duration of ART, becoming insignificant after 3 years on ART. This is 
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explained by noting that patients initiating ART at low baseline CD4 counts who survive at 
least 3 years on ART and attain current CD4 counts in excess of 200 cells/µl and suppressed 
viral loads (≤400 copies/ml) are estimated to achieve similar levels of relative risk after 3 years 
on ART as patients with high baseline CD4 counts. Current, not baseline, CD4 count and viral 
load were the most prognostic of future relative risk at any time point on ART.  
 
Relative risk exceeded the insurance industry threshold in only one subgroup with current CD4 
count 200+ cells/µl and an unsuppressed viral load (400+ copies/ml). This subgroup, however, 
represents only 11% of PYO observed from the first year of ART onwards (Figure 2). Adjusted 
relative risk in patients attaining current CD4 counts of ≤200 cells/µl and unsuppressed viral 
loads (400+ copies/ml) were 7.76 [6.87;8.93] times higher on average across durations on 
ART than in patients attaining current CD4 counts 200+ cells/µl and suppressed viral loads 
(≤400 copies/ml) (Appendix I). The remaining two subgroups (diagonal in Figure 3) maintained 
relative risk of approximately 3 across time. For the HIV cohort overall, 86%–90% of PYO 
remaining and 90% of patients at risk from all time points 6 months on ART or later 
corresponded to relative risk levels within the insurance industry threshold (<5) which 
suggests that a large majority of this HIV cohort would be eligible for insurance. Among 
patients attaining current CD4 counts of 200+ cells/µl and suppressed viral loads (≤400 
copies/ml) at 6 months on ART or later, 100% of PYO remaining and patients at risk 
corresponded to relative risk levels well below the insurance industry threshold (<5), 
suggesting clear evidence of insurability. Since this sub-group represents over 70% of PYO 
from the first year of ART onwards (Figure 2), this finding explains why a majority of this overall 
cohort has relative risk levels well below the insurance industry threshold.  
 
Relative to baseline CD4 count 200–349 cells/µl, adjusted relative risk in the <50, 50–99, 100–
199 and 350+ cells/µl strata were 1.22 [1.02,1.42], 1.21 [1.03,1.49], 1.01 [0.86,1.18] and 1.1 
[0.69,1.6] times higher, respectively. Given that patients in this cohort initiated ART historically 
at CD4 counts <350 cells/µl or at advanced clinical stage, the higher relative risk in baseline 
CD4 count 350+ cells/µl may be attributable to a higher proportion of patients starting ART at 
advanced clinical stage relative to the stratum baseline CD4 count 200–349 cells/µl. Adjusted 
relative risk declined with increasing current age partly because increases in mortality with 
age in the HIV cohort were less marked than in the control. Adjusted relative risk was 0.83 
times [0.76,0.89] lower in males and 1.59 [95% CI 1.3,1.88] times higher in the non-black 
population group, which is partly explained by mortality in the control (background) cohort 
being significantly lower in the non-black population. Given this significant differential in 
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relative risk by population group, the generalisability of the study findings is further explored 
in section 3.5.3, which compares relative risk in the HIV cohort with that in a large European 
cohort. Compared to baseline viral load 5log–6log copies/ml, adjusted relative risk was 0.82 
[0.77;0.88] times lower in the stratum 401–5log copies/ml and 1.28 [1.12;1.48] times higher in 
the stratum 6log+. Differences in adjusted relative risk per medical scheme group were 
insignificant (1.04 [95% CI 0.96,1.12]). 
 
Intermediate findings in reaching the final model started with a model including all variables 
and no interactions (Appendix H). Variables with clear associations (p-value<0.05) and where 
confidence intervals of adjusted relative risk ratios did not include 1 were initially included in 
the model. Medical scheme only was not significant (p-value =0.96 and adjusted relative risk 
ratio 1.00 [95% CI 0.97;1.03]). Notably, current CD4 count <200 cells/µl and suppressed viral 
load (≤400 copies/ml) had the largest effect (adjusted relative risk ratio 7.12 [95% CI 
6.84;7.41]). Patients that were currently on third-line treatment had 3.98 [95% CI 2.39;6.62] 
times the relative risk of patients currently on first-line treatment whereas patients currently on 
second-line were more comparable to those currently on first-line (1.09 [95% CI 1.04;1.15]). 
Other effects were relatively smaller but still significant (Appendix H). For some variables, e.g. 
the year of ART initiation, years were combined where the adjusted relative risk ratios were 
similar. The next step was to compare various models with different combinations of variables, 
initially without including interactions. All combinations of variables were tested and a group 
of models with the lowest AICc was identified (Appendix I shows the top 40 models with the 
lowest AICc values). Models with the lowest AICc values were broadly consistent with the 
above insights, using p-value significance and confidence intervals of adjusted relative risk 
ratios. Appendix H highlights the convergence of AICc amongst models with the lowest AICc.  
 
To obtain initial insights about which two-way interactions may be significant, a cross-validated 
(optimised tuning parameter) penalised Poisson glm regression (glmnet) was used, given its 
efficiency, interpretability, ability to relate HIV and control cohort deaths via an offset and its 
penalising of the Poisson model for having too many variables [47]. The LASSO form of glmnet 
was used, which shrinks to zero coefficients that do not improve model performance, a 
process also known as regularisation. Appendices J (all two-way interactions tested) and K 
(time since ART excluded) show the top 50 most influential model coefficients standardised to 
a consistent scale (green and red dots indicating upward and downward effects respectively 
of coefficients on relative risk). The interaction of baseline CD4 count 350+ cells/µl and current 
regimen (third-line) had the largest upward impact on relative risk, followed by the adjustment 
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for current CD4 count <200 cells/µl combined with an unsuppressed viral load (400+ 
copies/ml). The interaction of earlier years on ART initiation and current regimen (third line) 
also had a large impact on relative risk, as did the interaction of baseline regimen (second 
line) with the current regimen (third line) possibly indicating failure of a past regimen and 
changing regimen. Time since starting ART also interacted with baseline CD4 count and 
current CD4 count and viral load. 
 
Using the insights gained from testing two-way interactions, knowledge of published literature 
and actuarial and medical domain knowledge, models including selected interactions 
(indicated by *) in addition to univariate effects were ranked by AICc (Appendix L). While the 
model with the lowest AICc included interactions, 4 of the models with the lowest AICc 
excluded interactions and some excluded baseline and current regimens. A further step 
beyond AICc was to test differences in each model’s ability to predict relative risk in a sample 
of data excluded when fitting (training) each model (Appendix L). Numbers of predicted deaths 
per patient are compared to those observed in the HIV cohort and aggregated into a single 
Poisson deviance metric. Models with lower deviance achieve better goodness of fit. The 
deviance (values shown in both the table and graph of Appendix L) provides a measure of 
each model’s predictive power when measured on unseen (holdout) data. The blue line 
represents the AICc of each model fitted on the training data as before. Models with the lowest 
AICc value had similar levels of deviance, potentially indicating only marginal benefit from 
including interactions. Finally, Appendix M compares actual relative risk (marked ‘Study’ data 
in red) by current CD4 count, current viral load and time since starting ART, with predicted 
relative risk (again in the holdout data) from each of the models in Appendix L. Models were 
similar in general and within the confidence interval of observed relative risk. The shaded blue 
area represents the remaining follow-up time (PYO) from each time point on ART and showed 
clearly that confidence intervals were wider where patient volumes at risk were lower. 
 
The final choice of variables was made by considering: the generalisability of the results to 
other cohorts and settings; parsimony of models and credibility of their estimates, given 
available data; and applicability in insurance and relevance to future conditions that insurance 
pricing must be appropriate for. Population group is inappropriate for use in an insurance 
context but was considered meaningful for generalising the findings to other settings, given 
the differences in background mortality. Baseline regimen and year of ART initiation may be 
difficult to justify to customers, often relating to many years before the insurance application. 
The model with the lowest deviance included an interaction of baseline CD4 count with time 
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since starting ART and an interaction between current CD4 count and viral load and time since 
starting ART. These interactions were included in the final model and were also expected, 
given the published waning prognostic value of baseline CD4 count after adjusting for the 
response to ART. The final model adjusted relative risk ratios are provided in Appendix N 
 
Lastly, as a reasonability check and for informing subsequent discussion, Figure 4 shows all-
cause mortality estimates in the control group (‘Study’) by current (attained) age, gender and 
population group compared to various comparator populations (described in Figure 4). The 
control mortality compared reasonably with other comparators: significantly lower than South 
African general population all-cause mortality (given the significant proportion of HIV-related 
mortality), less than South African general population HIV-unrelated mortality (owing, inter-
alia, to differences in socio-economic profile and access to healthcare), and overall insured 
lives mortality within the range of the black and non-black control mortality. Non-black control 
mortality compared reasonably to SA85–90 for males at younger ages, which could be 
expected given the population group mix of insured lives and negligible HIV-related mortality 
in South Africa in the late 1980s. The black female control group exceeded general population 
HIV-unrelated morality but was in line with the worst socio-economic class of insured lives 
mortality. The non-black female control mortality was broadly similar in level to 50% of SA85–
90, which is considered reasonable. Finally, as expected, all of the above comparators 
significantly exceeded the background mortality used in the ART-CC relative risk study 
representing European insured lives [1]. 
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Figure 3: Adjusted (multivariate) relative mortality risk (with bootstrapped 95% confidence intervals) by time-updated CD4 count and viral load, baseline CD4 count 
and duration since initiating ART. Benchmarks included: control (relative risk = 1), DM2 cohort and insurance industry threshold (relative risk = 5)  
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Figure 4: Control cohort mortality incidence with a comparison to examples* of controls used in other studies (ART-CC, South African general population all-cause 
and HIV-unrelated mortality, South African insured-lives experience 
 
* Control (Study) mortality estimates are by 5-year age band (dashed line: 95% confidence intervals) and therefore appear stepped. ART-CC (background mortality used in the ART-CC relative risk study 
[1], excl. Netherlands or including). General population and General population (non-HIV): South African general population all-cause and HIV-unrelated mortality estimated using the Thembisa 3.2 
model (www.thembisa.org) for 2007 (mid-point of the control follow-up). Insured lives and Insured lives_worst class: most recently available (at the time of writing) South African insured lives mortality 
experience overall and within the worst socio-economic class (Actuarial Society of South Africa Assured Lives Mortality Investigations, 1999 – 2002). SA8590: 1985-1990 South African insured lives 
mortality experience is regarded as the last to have negligible HIV-related mortality (the ultimate duration was selected for illustration purposes). 
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3.6.3 Comparison with ART-CC methodology 
 
As mentioned earlier, section 3.5.2 estimates relative risk over all remaining follow-up (PYO) 
from a given time point since starting ART and not within a given interval (e.g. 1–3 years on 
ART). The ART-CC assessed the insurability of HIV-infected people in European cohorts [1] 
by estimating relative risk in defined intervals (durations) of ART and correctly points out that 
this format of relative risk is not directly applicable by insurers that require constant levels of 
average relative risk over a policy’s future lifetime. To increase the generalisability of the 
current study, the methodology used by the ART-CC is replicated on the study data and 
adjusted relative risk ratios are compared in Figure 5 for overlapping variables in both studies. 
Both estimates of adjusted relative risk ratios in Figure 5 represent the relative risk in defined 
intervals of ART as represented by the duration on ART variable. An adjusted relative risk ratio 
of 1 represents the reference category (dashed black line) within each variable.  
 
Both studies show remarkably similar relative risk ratios, except for CD4 count measured at 6 
months on ART <50 cells/µl and current age. However, the level of relative risk differed within 
the reference group, which was defined as patients with a 6-month CD4 count 350+ cells/µl, 
6-month viral load <10000 copies/ml, current age 20–39, duration on ART 0.5–3.5 years 
(although labelled as 1–3 years in the ART-CC study, this represents time starting from 6 
months on ART), baseline clinical CDC stage A/B, and year of ART initiation 2001–2008. 
Relative risk (HIV vs. control cohort all-cause mortality) was 4.59 and 1.57 in the ART-CC and 
study cohort reference groups, respectively. The much higher relative risk in the ART-CC 
study is partly explained by the relatively much lower background mortality in Europe and also 
by the fact that the ART-CC control represented insured lives that were medically screened 
not only for HIV but other medical impairments, further lowering the level of background 
mortality. (see Figure 4).  
 
A major and novel finding of our study comparison is that while the immunological and 
virological response to ART (adjusted relative risk ratios for the 6-month CD4 count and viral 
load measurements and duration on ART) was similar between the ART-CC and our cohort, 
the level of relative risk differed, as did the effect of current age on relative risk. When current 
age was interacted with population group in a further model (Appendix O), the effect of age 
on relative risk in the non-black population group compared very closely with that of the ART-
CC whereas the adjusted relative risk ratio for current age in the black population group had 
a very different shape. Notably, within the reference group relative risk in the black population 
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group was 1.55 (multiple of control mortality), compared to 4.81 in the non-black population, 
which compared very well with 4.59 in the ART-CC cohort. Relative risk in the study non-black 
population was 3.10 times that in the study black population (Appendix O). Appendix P shows 
that when modifying (interacting) the effect of current age on relative risk for population group, 
the effect of current age for the non-black population compares very closely with the effect of 
current age reported by the ART-CC cohort, particularly in ages 20–39, whereas the effect of 
current age for the black population group has a different shape. 
 
Figure 5: Replicating ART-CC methodology on study data 
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3.6.4 Sensitivity analyses 
 
3.6.4.1 More bands in current CD4 
 
Appendix Q expands Figure 3 to include more granular current CD4 count bands, e.g. <200, 
200–349, 350–499 and 500+ cells/µl. The left and right column of figures represent current 
suppressed (≤400 copies/ml) and unsuppressed viral loads (400+ copies/ml), respectively, 
measured at each time point. Within the black population group, patients attaining a current 
CD4 count of 200–349 cells/µl and a suppressed viral load had relatively higher relative risk 
compared to a current CD4 count of 350–499 and 500+ cells/µl in which relative risk 
approached 1, suggesting that mortality in these HIV subgroups of the black population group 
converged with their corresponding control cohort. However, the non-black population group 
relative risk was 1.6 [95% CI 1.46;1.75] (p-value 9.19E-24) times that in the black population 
group, which, while still within the insurance industry threshold, is higher than HIV uninfected 
levels of mortality. This sensitivity test of more granular current CD4 count strata provides 
additional granularity at a subgroup level. 
 
3.6.4.2 Comparison with DM2 
 
Figure 3 shows that relative risk in the DM2 cohort by time since starting DM2 therapy is higher 
than in the HIV cohort subgroup with lowest relative risk and similar to other subgroups except 
for current CD4 count 200+ cells/µl and an unsuppressed viral load (400+ copies/ml). 
Therefore, given that 90% of PYO from 1 year of ART onwards (Figure 2) corresponds to 
patients with better or comparable relative risk to the DM2 cohort (Figure 3), this suggests that 
the majority of patients in the HIV cohort have comparable relative risk to those with a chronic 
condition that is already insurable. 
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3.7 Discussion 
 
In 2013, the ART-CC assessed the insurability of HIV-infected people starting ART in Europe 
[1] and issued an urgent call for a corresponding study in South Africa where adult HIV 
prevalence (18.8%) in 2018 is over 60 fold that in Western and Central Europe and North 
America (0.3%) [48], where high life insurance market penetration exists. Our study responds 
to this call and, to our knowledge, is the first study outside of Europe to assess the insurability 
of HIV-infected adults starting ART. Strengths of our study include that it is based on one of 
the largest HIV-infected cohorts globally (77,325 patients) starting ART over the period 2000–
2013, with long follow-up time (median 3.23 years [IQR 2.04;5.30]), large numbers of deaths 
(8,920), accurate mortality ascertainment via the national death registry and the inclusion of 
baseline and time-updated patient characteristics. This compares with the 34,680 patients and 
1,236 deaths of the only other existing study on the insurability of HIV [1] globally. Further, our 
study compares the HIV cohort to an HIV-uninfected control cohort (comparator) and a DM2 
cohort starting DM2 therapy, both selected from the same medical schemes as the HIV cohort. 
Comparison of the DM2 and HIV cohorts provides a benchmark of HIV to a chronic condition 
which is already insured. To our knowledge, no study of the insurability and relative mortality 
risk of HIV-infected patients starting ART has achieved these study design strengths globally. 
 
In the overall HIV cohort, 86%-90% of PYO remaining and 90% of patients at risk from all time 
points 6 months or later since ART initiation corresponded to relative risk levels within the 
insurance industry threshold (<5), which suggests that a large majority of this HIV cohort is 
insurable. Among patients attaining current CD4 counts of 200+ cells/µl and suppressed viral 
loads (≤400 copies/ml) at 6 months on ART or later, 100% of PYO remaining and patients at 
risk corresponded to relative risk levels well below the insurance industry threshold (<5), 
suggesting clear evidence of this cohort’s insurability. Since this sub-group represents over 
70% of PYO from the first year of ART onwards (Figure 2), this finding explains why a majority 
of this overall cohort has relative risk levels well below the insurance industry threshold. Of 
PYO from 1 year of ART onwards (Figure 2), 90% corresponds with patients with lower or 
comparable relative risk to the DM2 cohort (Figure 3), implying that the majority of patients in 
the HIV cohort have a comparable relative risk to those with a chronic condition that is already 
insured.  
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The methodology presented in this analysis is novel since relative risk is measured from a 
given duration of ART, is conditional on the current (updated) and baseline characteristics at 
that time and is calculated over all remaining follow-up as a longer-term average. Our method, 
therefore, contributes significantly to meeting the needs of insurers for relative risk estimates 
that remain constant over the future policy lifetime at the long-term average. The ART-CC 
correctly points out that since relative mortality risk varies with current age and time on ART, 
no single result from their adjusted relative risk ratios applies to a given insurance policy [1] 
and requires further actuarial methods for converting varying relative risk ratios so as to obtain 
a constant level of relative risk across the policy lifetime. Our novel methodology addresses 
not only this limitation of the ART-CC study but also enables insurers to assess future relative 
risk based on CD4 counts and viral loads measured nearest to the time of applying for 
insurance as opposed to at 6 months on ART, potentially many years ago. The latter is crucial, 
given that insurance applicants on ART increasingly apply for insurance at longer durations of 
ART and may no longer have records of their 6-month measurements. Insurers, meanwhile, 
may deem it unreasonable to request this. Further, our study shows that the prognostic value 
of the 6-month CD4 count and viral load is different from corresponding measurements at later 
durations of ART, suggesting a diminishing value of the ART-CC results for insurers assessing 
applicants at longer durations of ART. This is supported by other studies focussing on mortality 
in South Africa [49].  
 
To our knowledge, our study is the first globally to estimate relative risk using both baseline 
and current characteristics and where the prognostic value of current characteristics is 
measured from multiple time points. Our study shows that the baseline CD4 count has 
prognostic value after adjusting for the immunological and virological response to ART (time-
updated CD4 and viral load). However, the prognostic value wanes as time on ART increases, 
becoming negligible after 3 years of ART. The ART-CC reports that after adjusting for the CD4 
count and viral load at 36 months on ART, baseline and the 6-month CD4 count and viral load 
were not significant in predicting mortality beyond 36 months [50]. This study, however, does 
not report relative risk. The IeDEA collaboration found a similar waning effect of baseline CD4 
count in South African adults starting ART followed for 2 years on ART [51] as did another 
ART-CC study [52] assessing mortality in up to 15 years of follow-up. However, both studies 
only include baseline CD4 counts and do not include time-updated CD4 count and viral load 
and, therefore, cannot assess the prognostic value of baseline CD4 count after controlling for 
the response to ART. Another ART-CC study [31] found that at 6 months after starting ART, 
the current CD4 cell count and viral load, not the baseline measurements, were more 
prognostic of subsequent disease progression, but this study does not assess whether the 
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prognostic value of the response to ART, when measured at later durations, is different than 
when measured at 6 months. The above studies are of limited value to insurers in that they 
do not quantify the effect of baseline CD4 count on relative risk measured from multiple time 
points on ART while controlling for the current CD4 count and viral load measured at these 
time points. Our study, therefore, better meets the needs of insurers. 
 
Multiple stakeholders have an interest in knowing which subgroups of HIV-infected patients 
starting ART may achieve HIV-uninfected levels of mortality. We found that relative risk was 
lowest in patients attaining a current CD4 count of 200+ cells/µl and a suppressed viral load 
(≤400 copies/ml) and reduced with time on ART, approaching 1 after 3 years on ART. 
However, in the non-black population group, relative risk was 1.59 [95% CI 1.30;1.88] times 
that in the black population group. This, while still implying relative risk levels within the 
insurance industry threshold, implies higher mortality than HIV-uninfected levels of the control. 
In understanding whether South African adults successfully treated on ART can attain HIV-
uninfected levels of mortality, our findings address some weaknesses in existing studies. First, 
as patients survive to increasingly longer durations on ART, there is a need for patients, 
healthcare practitioners, ART programmes, other modellers, insurers and policymakers to 
understand the prognosis from later durations on ART based on current characteristics. Our 
study estimates relative risk measured from multiple time points on ART using current (time-
updated) characteristics and shows that the effect of the baseline CD4 count wanes after 3 
years on ART, after which current characteristics are most prognostic. Second, since the HIV, 
DM2 and control cohorts were chosen from the same medical scheme population, greater 
comparability was achieved between the cohorts than was possible in other studies using the 
general population or insured-lives [1] as a control. The control cohort represented a very large 
population (over 500,000 patients) observed over long follow-up (median follow-up 7.24 
years). Third, the medical scheme population from which the HIV, DM2 and control cohorts 
were selected more accurately matches (is a better proxy for) the risk profile of people 
purchasing insurance in terms of socio-economic profile and access to health care and, 
therefore, has greater generalisability to our insurance context than studies using HIV-
unrelated mortality of the general South African population. Fourth, the control could be 
matched with the HIV and DM2 cohorts by age, gender and population group, which increases 
the accuracy of the relative risk given observed differences in background mortality by 
population group. Other South African studies could introduce a mismatch between the study 
and control cohorts where population group was not available in both cohorts. Fifth, we believe 
that using relative mortality risk better addresses this question than comparing the ratio of life 
expectancies of patients starting ART with life expectancies based on HIV-unrelated mortality 
67 
 
in the general population [11]. Sixth, with 80% to 90% of adult deaths recorded through the 
country’s vital registration system [33, 53] South Africa is perhaps the only country in Africa 
with adequate vital registration levels to enable independent ascertainment of mortality [54]. 
Mortality ascertainment for the HIV, DM2 and control cohorts was achieved via linkage with 
the national death registry, which improves the credibility of mortality estimates. Finally, along 
with time-updated risk factors and large volumes of deaths, our study included long follow-up, 
which is difficult to achieve in ART programmes in low-income countries [55, 56]. 
 
Beyond our novel methodology, our study included a further analysis that replicated the ART-
CC methodology on a South African cohort, the results of which increase the generalisability 
of our study to other settings. Our findings show that while the immunological and virological 
response to ART in our study and the ART-CC study were similar, differences across 
population groups were observed in the level of relative risk and the effect of age on relative 
risk. Only the non-black population group had levels of relative risk and age adjustments that 
were comparable to the ART-CC. Notably, within the reference group, relative risk in the black 
population group was 1.55 (multiple of control mortality) as compared to 4.81 in the non-black 
population, which fell within the confidence interval reported by the ART-CC [1] 4.59 [95% CI 
3.91;5.39]. Other studies [57] have suggested a similar immunological and virological 
response to ART in LMIC and HIC settings and that, while mortality on ART in LMIC has been 
much higher in the initial months of ART, timely diagnosis and earlier initiation of and free 
access to ART may reduce this excess mortality [58]. Further, while other studies report that 
with increasing duration on ART, mortality on ART in South Africa is estimated to decline to 
lower or comparable levels in North American cohorts and to be significantly closer to that in 
European cohorts [59], they do not report differences in relative risk. Further, the ART-CC 
includes patients with baseline viral load <500 copies/ml (8% of patients) whereas our study 
excluded patients believed to already have started ART defined by baseline viral load ˃400 
copies/ml. A limitation of our comparison to the ART-CC study is that we did not have CDC 
clinical stage in our data and therefore could not adjust for that. 
 
In an insurance context, the insurance coverage remains in place regardless of whether the 
policyholder is adherent or LTFU after purchasing the policy. Since mortality could be 
accurately ascertained via linkage with the national death registry, no further adjustment was 
considered necessary for patients LTFU. Insurers should, however, consider changing levels 
of LTFU and adherence and the associated impact on mortality when setting estimates of 
relative risk that have to be appropriate for future conditions. 
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This is the first large-scale study to evaluate relative mortality in a cohort with a large sample 
size and well-defined and documented clinical, immunological and virological outcomes. While 
the study is informative and innovative, our findings should be considered alongside their 
limitations and recommended steps to address them. The differential in relative risk by 
population group could be partly attributable to non-similarities or a different mix of 
characteristics between population groups in the HIV and control cohorts that could not be 
adjusted for with the available variables e.g. socio-economic variables. However, this 
difference is thought to be minimal, given that the HIV and control cohorts are selected from 
the same medical scheme population. Relatively higher residual variation (actual relative risk 
vs. modelled) remained in certain subgroups compared to others and could potentially be 
caused by not including other variables; for example baseline clinical stage was not available 
and could have long-term prognostic value independent of other variables [60]. If the 
distribution of such variables changes within available subgroups, this could result in lower 
accuracy of the model in certain subgroups. Further, prevailing ART initiation guidelines 
recommended ART initiation from baseline CD4 counts ≤350 cells/µl or upon advanced clinical 
stage (e.g. WHO stage 4 illnesses). Patients initiating at a CD4 count ˃ 350 cells/µl historically, 
therefore, did so on the basis of advanced clinical stage, which is believed to have largely 
resulted in this group having higher mortality than patients initiating at a CD4 count of 200–
349 cells/µl. Patients initiating at CD4 counts ˃350 cells/µl historically, therefore, cannot be 
generalised to patients starting above 350 cells/µl today. The latter are much less likely to 
have advanced clinical stage due to current guidelines recommending earlier ART initiation 
from diagnosis (independent of CD4 count). Our findings (Appendix C) also show a strong 
increasing trend in baseline CD4 count. Meanwhile, we did not impute missing values, which 
should be done using Rubin’s multiple imputation [61] to deal with missing baseline and time-
updated CD4 and viral loads. However, time-updated measurements were estimated every 6 
months, as described under ‘Methods’, which provided estimates in some cases of time-
updated measurements where they were otherwise missing. We did not have follow-up 
beyond 12 years on ART and could not assess longer-term complications of ART, e.g. an 
increased risk of non-communicable disease [62]. This is relevant for insurers since whole life 
cover extends until death, potentially more than 70 years into the future.  
 
We did not consider the first 6 months of ART, similarly to the ART-CC [1]. Requiring insurance 
applicants to have been on ART for at least 6 months at the time of applying for insurance 
provides highly prognostic information contained in the response to ART and indirectly about 
adherence to ART [63]. Early mortality observed historically in the early months on ART has 
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been significant, as shown by a general review of early mortality in SSA [64] and a systematic 
review of early mortality in LMICs [65], where key drivers of early mortality were severe 
baseline immunosuppression and advanced baseline HIV clinical stage, demographic, socio-
economic and health service risk factors. However, patients initiating ART in 2019 and beyond 
are initiating ART on the basis of current ART clinical guidelines that recommend ART initiation 
from diagnosis independent of CD4 count. Such patients could be expected to initiate ART at 
increasingly lower CD4 counts and from earlier clinical stages, which should contribute to 
reduced early mortality. Our study further shows a strong trend of increasing baseline CD4 
count (Appendix C). Insurers should, therefore, continue to review studies considering the risk 
in the initial 6 months of ART.  
 
In the DM2 cohort, HbA1c was not available. We, therefore, could not identify a subgroup of 
DM2 patients that were well controlled on DM2 therapy for comparison with the corresponding 
subgroup of the HIV cohort; research of relative risk using HbA1c is required. 
 
The control was selected to be HIV-uninfected at all time points by screening for historic 
medical scheme claims for CD4 or viral load tests and ART medication. It is possible that a 
small group of HIV positive and undiagnosed members of the scheme was included in the 
control. However, this is believed to be negligible given the combination of the shift in clinical 
guidelines to ART initiation from earlier stages, the trend observed of earlier ART initiation 
from less advanced stages of disease and that over 90% of HIV-positive people in South Africa 
are estimated to know their status in 2019 [18] and are eligible now for ART. The DM2 cohort 
definition had the limitation that, being on anti-diabetic medication, would not have detected 
DM2 patients managed with diet alone. 
 
Regarding application in insurance, we could only estimate relative risk within the observation 
period. In insurance practice, calculation of evidence-based relative risk for long-term 
insurance requires additional extrapolation of relative risk estimates beyond that of 
observation periods in cohort studies. However, given that our study and the ART-CC [1] found 
that relative risk in HIV-infected people on ART declines with increasing age and time on ART, 
use of our relative risk estimates for longer periods could be argued as prudent for insurance 
purposes. A counter argument to this could be the increasing risk of non-communicable 
disease as patients survive longer on ART [62]. Other underwriting challenges include the 
likely future adherence to ART, the quality of healthcare, presence of co-morbidities and drug 
interactions. Comorbidities that are present in many patients starting ART in resource-poor 
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settings include tuberculosis, invasive bacterial and fungal infections that might increase 
mortality [66-68] considering that access to prophylaxis, diagnostic facilities and effective 
treatment for opportunistic infections is often limited in these settings [58]. 
 
Some South African studies have included a comparison with the general population but have 
focussed on life expectancy [11] using only baseline characteristics and require assumptions 
of mortality at longer durations on ART, often extrapolated from mortality estimated in short 
follow-up periods.  Another study of mortality after ART initiation in sub-Saharan Africa claimed 
that life expectancy of patients initiating ART cannot be estimated [69] from similarly short 
follow-up periods. Our study may inform future studies on the life expectancy of HIV-infected 
patients starting ART using relative risk estimated by baseline and current characteristics and 
over longer follow-up periods. 
 
This study has important implications for the insurance industry and the insurability of HIV in 
South Africa as uncertainty around long-term mortality on ART has, historically, been a key 
factor influencing the decisions of life insurers to offer long-term cover (whole-of-life policies) 
to HIV-infected people. Further, the findings have been cited in international publications [70, 
71]. In summary, this analysis of a large cohort from the South African private sector 
programme suggests that the vast majority of cohorts resembling this cohort are insurable. 
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4 Conclusion 
 
4.1 Overview 
 
While the dramatic scale-up of ART has reduced adult HIV-related deaths in South Africa by 
around 70% between the peak in 2005 and 2019 and mortality rates specifically in South 
African adults on ART, have declined [1, 2], existing studies do not assess which patient 
subgroups, defined by both baseline and current (time-updated) characteristics, achieve HIV-
uninfected levels of mortality and which subgroups have relative mortality that is within the 
insurance industry’s threshold for insurability. Some repetition below from the above 
discussion is explained by the intention to submit the previous section as a self-standing 
journal paper. 
 
At the time of initiating this research in 2013/2014, some insurers were declining HIV-infected 
South Africans applying for higher cover amounts spanning the whole of life. Further, since 
other chronic conditions such as DM2 were already insurable, a question of equity in the 
treatment of chronic conditions arises. At the same time, the ART Cohort Collaboration (ART-
CC) assessed the insurability of HIV-infected people starting ART in Europe and issued an 
urgent call for a corresponding study in South Africa where adult HIV prevalence (19%) in 
2019 [1] is over 60-fold that in Eestern and Central Europe and where high life insurance 
market penetration exists. This study responds to this call and, to the author’s knowledge, is 
the first study outside of Europe to assess the insurability of HIV-infected adults starting ART. 
This study is also the first to compare the relative mortality of South African HIV-infected adults 
initiating ART using an HIV-uninfected control (comparator) chosen from the same 
subpopulation, measured from multiple time points on ART using both baseline and current 
(time-updated) characteristics, long follow-up times, significant patient volumes and accurate 
mortality ascertainment. Patient subgroups, defined by both baseline and current 
characteristics, were identified with insurable levels of relative mortality as well as with 
subgroups that attain HIV-uninfected levels of mortality. This study provides a novel relative 
survival methodology that can inform further modelling of the impact on mortality in South 
Africa by achieving the 90-90-90 targets [3]. The study significantly contributes to reducing 
uncertainty around long-term survival on ART, which had been a key factor influencing the 
decisions of life insurers historically to offer long-term cover to HIV-infected people at higher 
cover amounts. The study significantly contributes to expanding the insurability of HIV while 
ensuring actuarial soundness and treating insurance customers fairly.  
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4.2 Summary of key findings 
 
In the overall HIV cohort, 90% of patients at risk from all time points 6 months or later since 
ART initiation were estimated to have relative risk within the insurance industry threshold (<5), 
suggesting that a large majority of this HIV cohort is insurable. Among patients attaining 
current CD4 counts of 200+ cells/µl and suppressed viral loads (≤400 copies/ml) at 6 months 
on ART or later, 100% of patients at risk corresponded to relative risk levels well below the 
insurance industry threshold (<5). Of of patients at risk from 1 year of ART onwards, 90% had 
a lower or comparable relative risk to the DM2 cohort, implying that the majority of this HIV 
cohort had a comparable relative risk to the DM2 cohort, representing a chronic condition that 
is already insurable. 
 
Patients attaining a current CD4 count of 200+ cells/µl and a suppressed viral load (≤400 
copies/ml) had the lowest relative risk, reducing with time on ART and approaching 1 after 3 
years on ART in the black population group, indicating attainment of HIV-uninfected mortality 
levels within the remaining follow-up below 13 years since starting ART. However, in the non-
black population group, relative risk was 1.59 [95% CI 1.30;1.88] times higher than in the black 
population group which, while still within the insurance industry threshold, implies higher 
mortality than HIV-uninfected levels in the non-black population group. The differential in 
relative risk by population group could be partly attributable to non-similarities or a different 
mix of characteristics between population groups in the HIV and control cohorts, e.g. socio-
economic variables, that could not be adjusted for with the available variables. However, this 
difference is thought to be minimal given that the HIV and control cohorts are selected from 
the same medical scheme population. Other non-similarities are discussed in the strengths 
and weaknesses section below. 
 
Baseline CD4 count was only prognostic for relative risk within the first 3 years of ART after 
adjusting for the immunological and virological response to ART measured by current CD4 
count and viral load. This is an important finding as insurance applicants on ART increasingly 
apply for insurance at longer durations of ART and may only have current characteristics 
available, may no longer have records near to ART initiation and insurers may deem it 
unreasonable to request such records of applicants many years later. Further, this study and 
others [4] suggest that the prognostic value of CD4 count and viral load is different when 
measured at different durations of ART, which enables insurers and other stakeholders to 
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assess the future relative risk when measured from multiple time points on ART using current 
characteristics. The ART-CC reported relative risk based on the 6-month CD4 count [5] but 
showed in another study that the 6-month CD4 count, when adjusting for the 36-month CD4 
count, is not prognostic for mortality beyond 36 months on ART [6]. The novel approach 
presented in this thesis enables insurers to assess relative risk based on the time since 
starting ART at the time of applying for insurance, current CD4 count and viral load and 
baseline CD4 count. The findings are also important for other modellers who need to consider 
the interaction of baseline and current characteristics and time since starting ART. 
 
Other studies [7] have suggested a similar immunological and virological response to ART 
between LMICs and HIC settings and that while mortality on ART in LMIC has been much 
higher in the initial months of ART, timely diagnosis and earlier initiation of and free access to 
ART may reduce this excess mortality [8]. Other studies report that with increasing duration 
on ART, mortality on ART in South Africa was estimated to decline to lower or comparable 
levels in North American cohorts and to be significantly closer to that in European cohorts [9]. 
This thesis includes an additional analysis that replicates the ART-CC methodology [5] on the 
study data. The immunological and virological response to ART between this study and the 
ART-CC study was found to be similar, although the level of relative risk was similar only in 
the non-black population group and, further, the effect of current age on relative risk was 
strongly modified by population group. Similar comments to the above (on potential non-
similarities between population groups in the HIV and control cohorts that could not be 
adjusted for with the available data) apply. 
 
4.3 Strengths and limitations 
 
Strengths of this thesis study include that it is based on one of the largest HIV-infected cohorts 
globally starting ART, with long follow-up times (which are difficult to achieve in low-income 
countries [10, 11]), large numbers of deaths, and accurate mortality ascertainment via the 
national death registry, which contributes towards greater credibility of mortality estimates. It 
includes both baseline and current patient characteristics, unlike most South African studies. 
Further, it compares three cohorts, namely HIV-infected adults starting ART, an HIV-
uninfected and DM2-negative control (comparator) and a DM2 cohort starting DM2 therapy, 
all selected from the same medical scheme subpopulation. Comparison of the DM2 and HIV 
cohorts provides the benchmark of a chronic condition which is already insured, thereby 
promoting equity. 
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The methodology presented in this analysis is novel since survival on ART is measured by 
relative risk. Further, this study measures relative risk from a given duration of ART, 
conditional on the current (updated) and baseline characteristics at that time and calculated 
over all remaining follow-up as a longer-term average. The method, therefore, contributes 
significantly to meeting the needs of insurers for relative risk estimates that remain constant 
over the future policy lifetime at the long-term average. In contrast, the ART-CC estimates 
relative risk in defined intervals of ART and points out that since relative risk varies with current 
age and time on ART, no single result from their analysis applies to a given insurance policy 
and further actuarial methods are required for converting varying relative risk ratios so as to 
obtain a constant level of relative risk across the policy’s lifetime [5].  
 
To the author’s knowledge, this study is the first globally to estimate relative risk from repeated 
6-monthly time points on ART. This enables insurers to assess future relative risk based on 
CD4 counts and viral loads measured nearest to the time of applying for insurance as opposed 
to at 6 [5] or 36 months [6] on ART, potentially many years prior to applying for insurance.  
 
The methodology enabled the finding that the prognostic value of current CD4 count and viral 
load measurements for future relative risk is different when measured at different times since 
starting ART. This finding is further supported by other studies of mortality in South Africa [4]. 
This suggests a diminishing value of the ART-CC results [5] for insurers assessing applicants 
at longer durations of ART. Other studies that have reported a waning prognostic value of 
baseline CD4 count in the initial years of ART either have a short observation period and do 
not analyse the interaction with current characteristics [7] or analyse mortality only and do not 
include a suitable control to estimate relative risk [12] or report the changing effect of baseline 
[6, 13, 14]. This thesis shows that the prognostic value of baseline CD4 count for relative risk 
wanes in the first 3 years of ART after adjusting for the immunological and virological response 
to ART. The above studies are of limited value to insurers in that they do not quantify the effect 
of baseline CD4 count on relative risk measured from multiple time points on ART while 
controlling for the current CD4 count and viral load measured at those time points. This thesis 
is therefore informative for multiple stakeholders needing to understand the prognosis of 
patients using current information at later durations of ART. 
In understanding if South African adults successfully treated on ART can attain HIV-uninfected 
levels of mortality, the findings address some weaknesses in existing studies. First, as patents 
survive to increasingly longer durations of ART, there is a need for patients, healthcare 
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practitioners, ART programmes, other modellers, insurers and policymakers to understand the 
prognosis from later durations on ART based on current characteristics. The thesis estimates 
relative risk measured from multiple time points on ART using current characteristics and 
shows that the effect of the baseline CD4 count wanes after 3 years on ART after which current 
characteristics were most prognostic. Second, since the HIV, DM2 and control cohorts were 
chosen from the same medical scheme population, greater comparability was achieved 
between the cohorts which was not possible in other studies using the general population [7] 
or insured-lives [1] as a control. The control cohort represented a very large population (over 
500 000 patients) observed over long follow-up (median follow-up 7.24 years). Third, the 
medical scheme population from which the HIV, DM2 and control cohorts were selected, more 
accurately matches (is a better proxy for) the risk profile of people purchasing insurance in 
terms of their socio-economic profile and therefore has greater generalisability to the 
insurance context than studies using HIV-unrelated mortality of the general South African 
population. Fourth, the control could be matched to the HIV and DM2 cohorts by age, gender, 
population group and medical scheme which increases the accuracy of the relative risk given 
the concern of confounding non-similarities. Other South African studies could introduce a 
mismatch between the study and control cohorts where population group was not available in 
both cohorts. Fifth, relative mortality is considered a more relevant measure for identifying 
which subgroups attain HIV-uninfected mortality than comparing the ratio of life expectancies 
of patients starting ART, using extrapolations of observed mortality, to life expectancies based 
on HIV-unrelated mortality in the general population reported by others [15]. Sixth, mortality 
was ascertained was for the HIV, DM2 and control cohorts via linkage with the national death 
registry which improves the credibility of mortality estimates.  
 
Beyond our novel methodology, our study included a further analysis that replicated the ART-
CC methodology [5] on a South African cohort, the results of which increase the 
generalisability of our study to other settings. Findings in this thesis show that while the 
immunological and virological response to ART was similar to that reported by the ART-CC 
study, differences across population groups were observed in the level of relative risk and the 
effect of age on relative risk. Only the non-black population group had levels of relative risk 
and age adjustments that were comparable to the ART-CC. Notably, within the reference 
group, relative risk in the black population group was 1.55 (multiple of control mortality) 
compared to 4.81 in the non-black population which fell within the confidence interval reported 
by the ART-CC [1] 4.59 [95% CI 3.91;5.39]. Further, the ART-CC includes patients with 
baseline viral load <500 copies/ml (8% of patients) whereas our study excluded patients 
believed to already have started ART defined by baseline viral load ˃400 copies/ml. A 
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limitation of our comparison to the ART-CC study is that we did not have CDC clinical stage 
in our data and therefore could not adjust for that. 
 
In an insurance context, the insurance coverage remains in place regardless of whether the 
policyholder is adherent or LTFU after purchasing the policy. Since mortality could be 
accurately ascertained via linkage with the national death registry, no further adjustment was 
considered necessary for patients LTFU. Insurers should, however, consider changing levels 
of LTFU and adherence [16] and the associated impact on mortality when setting estimates of 
relative risk that have to be appropriate for future conditions. 
 
While this is the first large-scale study to evaluate relative mortality in a cohort with a large 
sample size and well-defined and documented clinical, immunological, and virological 
outcomes, limitations of the findings should be considered together with future research to 
address them. First, the thesis is observational and may suffer from selection biases and non-
similarities in the HIV, DM2 and control cohorts. However, the cohorts could be matched by 
age, gender, population group and medical scheme and are selected from the same medical 
scheme population which should remove some bias and confounding from non-similarities. 
Second, since the study is based on a private sector medical scheme, the findings have limited 
generalisability to the general population but do have high generalisability to the insurance 
context. Beyond differences in characteristics such as socio-economic variables, differences 
in overall cohort outcomes exist. For example, in 2019 50-56% of adult patients on ART in 
South Africa were estimated to be virologically suppressed [1] compared to over 80% in this 
study cohort. 
 
The differential in relative risk by population group could be partly attributable to non-
similarities or a different mix of characteristics between population groups in the HIV and 
control cohorts that could not be adjusted for with the available variables. For example, socio-
economic variables, however this difference is thought to be minimal given that the HIV and 
control cohorts are selected from the same medical scheme population and further matched 
by age, gender and population group.  
 
The model may not fully capture variation in relative risk by baseline clinical stage since 
baseline clinical stage was not available and could have long-term prognostic value 
independent of other variables [17]. Further, prevailing ART initiation guidelines recommended 
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ART initiation from baseline CD4 counts ≤350 cells/µl or upon advanced clinical stage (e.g. 
WHO stage 4 illnesses). Patients initiating at a CD4 count ˃350 cells/µl historically therefore 
did so on the basis of advanced clinical stage which is believed to have largely resulted in this 
group having higher mortality than patients initiating at a CD4 count of 200-349 cells/µl. 
Patients initiating ART at CD4 counts ˃350 cells/µl historically, therefore, cannot be 
generalised to patients starting above 350 cells/µl in recent years and in future who are much 
less likely to have advanced clinical stage due to current guidelines recommending earlier 
ART initiation from diagnosis (independent of CD4 count). The findings (Appendix C) also 
show a strong increasing trend in baseline CD4 count.  
 
Further, imputation of missing values was not performed which should be done using Rubin’s 
multiple imputation [79] to deal with missing baseline and time-updated CD4 and viral loads. 
However, time-updated measurements were estimated in certain periods as described in the 
methods [18] to reduce some bias in time-updated measurements.  
 
The study did not consider the first 6 months of ART, similarly to the ART-CC [1]. Requiring 
insurance applicants to have been on ART for at least 6 months at the time of applying for 
insurance provides highly prognostic information contained in the response to ART and 
indirectly about adherence to ART [28]. Early mortality observed historically in the early 
months on ART has been significant as shown by a general review of early mortality in SSA 
[20] and a systematic review of early mortality in LMIC [81] where key drivers of early mortality 
were severe baseline immunosuppression and advanced baseline HIV clinical stage, 
demographic, socio-economic and health service risk factors. However, patients initiated ART 
in 2019 and beyond are initiating ART on the basis of current ART clinical guidelines that 
recommend ART initiation from diagnosis independent of CD4 count. Such patients could be 
expected to initiate ART at increasingly lower CD4 counts and from earlier clinical stages 
which should contribute to reduced early mortality. Further our study further shows a strong 
trend of increasing baseline CD4 count (Appendix C). Insurers should, therefore, continue to 
review studies consider the risk in the initial 6 months of ART.  
 
In the DM2 cohort, HbA1c was not available. The study therefore could not identify a subgroup 
of DM2 patients that were well controlled on DM2 therapy for comparison with the 
corresponding subgroup of the HIV cohort and research of relative risk using HbA1c is 
required. 
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The control was selected to be HIV uninfected at all time points by screening for historic 
medical scheme claims for CD4 or viral load tests and ART medication. It is possible that a 
small group of HIV positive and undiagnosed members of the scheme was included in the 
control. However, this is believed to be negligible given the combination of the shift in clinical 
guidelines to ART initiation from earlier stages, the trend observed of earlier ART initiation 
from less advanced stages of disease and that over 90% of HIV-positive people in South Africa 
are estimated to know their status in 2019 [82] and are eligible now for ART. 
 
Regarding application in insurance, the study can only estimate relative risk within the 
observation period and only had follow-up until 13 years on ART.  The study cannot assess 
the impact of longer-term complications of ART on relative risk, e.g. an increased risk of non-
communicable disease [80]. This is relevant for insurers since whole life cover extends until 
death, potentially more than 70 years into the future. In insurance practice, calculation of 
evidence-based relative risk for long-term insurance requires additional extrapolation of 
relative risk estimates beyond that of observation periods in cohort studies. However, given 
that this study and the ART-CC [5] found that relative risk in HIV-infected people on ART 
reduces with increasing age and time on ART, use of the study’s relative risk estimates for 
longer periods could be argued as prudent for insurance purposes. A counter-argument to this 
could be the increasing risk of non-communicable disease as patients survive longer on ART 
[19]. Other challenges for insurers include changes in adherence on ART and the quality of 
healthcare under NHI, presence of co-morbidities and drug interactions. Comorbidities that 
are present in many patients starting ART in resource-poor settings include tuberculosis, 
invasive bacterial and fungal infections might have increased mortality [20-22] considering that 
access to prophylaxis, diagnostic facilities, and effective treatment for opportunistic infections 
is often limited these setting [8]. 
 
This study has important implications for the insurance industry and the insurability of HIV in 
South Africa as uncertainty around long-term mortality on ART has, historically, been a key 
factor influencing the decisions of life insurers to offer long-term cover (whole-of-life policies) 
to HIV-infected people. The findings are deemed to be sufficiently robust for application in the 
insurance context and have already been cited within international publications [23, 24]. In 
summary, this analysis of a large cohort from the South African private sector programme 
suggests that the vast majority of cohorts resembling this cohort are insurable. The study 
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provides a practical approach to insurability that will also benefit future modelling in the public 
health community. 
 
4.4 Policy recommendations 
 
This research has been presented at many conferences including the largest actuarial 
conference globally, namely the International Congress of Actuaries in 2014, Washington D.C. 
The presentation was the first to cover the insurability of HIV based on a study with the 
abovementioned design strengths. Subsequently, many insurers in South Africa, North 
America and Europe have adapted the findings for their purposes with some of South Africa’s 
largest insurers starting to insure HIV-infected people for the whole of life at high cover 
amounts. This has contributed to reduced stigma, increased equity and access for HIV-
infected people to financial services that aim to create financial resilience in society.  
 
Mortality in patients in this cohort with a current CD4 count of 200+ cells/µl and a suppressed 
viral load (≤400 copies/ml) approached HIV-uninfected levels after 3 years on ART in the black 
population group, representing 96% of the HIV cohort. Relative mortality and the 90-90-90 
targets both represent relative measures. A potential policy recommendation is that further 
modelling and monitoring of the impact on mortality in South Africa from aspiring to the 90-90-
90 targets [3] should estimate and track relative mortality. This monitoring may provide 
additional insight into the ongoing demographic impact of HIV despite achieving the 90-90-90 
targets. Further, since HIV continues to account for a significant proportion of adult mortality 
[25], the changing cause-of-death mix within HIV-infected people should be monitored for 
signs of an increased risk of NCDs as patients survive to longer durations of ART [19].  
 
Similarly, the measurement of mortality is essential for tracking the targets of the South African 
Declaration on the Prevention and Control of NCDs. Targets for reducing mortality attributable 
to NCDs in the latter declaration are based only absolute numbers of deaths. A 
recommendation is that relative mortality for NCDs is estimated and monitored. This thesis 
analyses a large cohort of DM2 patients starting DM2 therapy in South Africa and provides a 
possible broad reference point of relative mortality to inform future modelling to monitor 
progress in achieving targets. This is particularly important considering that relative mortality 
in DM2 increases with duration of therapy, unlike HIV which, in periods of observation up to 
15 years of ART, has decreased overall with increasing duration of ART. 
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National health insurance (NHI) aims to enable universal, equitable, and affordable healthcare 
by phasing in the re-design of primary health care over 14 years. NHI has been piloted in ten 
selected health districts and initial audits suggest that few facilities comply with existing 
standards and include long waiting times and interruption of treatment due to non-availability 
of medicines [26]. This thesis shows the remarkable impact of ART on relative mortality in 
patients attaining and maintaining virological suppression and restoration of CD4 counts. 
Therefore, achieving the 90-90-90 targets has the potential to reduce the cost of NHI and it is 
crucial that challenges in rolling out and sustaining NHI do not interrupt access to ART and 
risk patients becoming virologically unsuppressed. While 4.77 million HIV-infected South 
African are estimated to be on ART in 2019, roughly 40% of HIV-infected South Africans are 
not yet initiated on ART [1] and closing this gap is a challenge to the capacity of a health 
system [26] that is already strained by a quadruple disease burden including HIV, tuberculosis 
and NCDs.  
 
4.5 Recommendations for future research 
 
Further research is proposed to address deficits in the available data such as to update the 
analysis to include baseline and time-updated WHO clinical stage and to update the cohort to 
include further years of follow-up on ART. 
 
Given the updated ART initiation guidelines and the 90-90-90 targets, which advocate for 
knowing your status early, starting ART irrespective of CD4 count and emphasise adherence 
to ART, further research should assess whether insurers could waive a requirement for 
applicants to have been on ART for at least 6 months and to demonstrate a suppressed viral 
load prior to being eligible for insurance cover.   
 
The study is limited by the available observation of 13 years on ART at most. Further research 
is needed into relative mortality at longer durations of ART and specifically the increased risk 
of NCDs. 
 
HBA1c for DM2 was not available and should be included in further research to identify 
subgroups of DM2 patients and the differences in relative risk. 
85 
 
 
4.6 References 
 
1. Johnson, L.F., et al., Estimating the impact of antiretroviral treatment on adult mortality 
trends in South Africa: A mathematical modelling study. PLoS Med, 2017. 14(12): p. 
e1002468. 
2. Granich, R., et al., Trends in AIDS Deaths, New Infections and ART Coverage in the Top 30 
Countries with the Highest AIDS Mortality Burden; 1990–2013. PLoS ONE, 2015. 10(7): p. 
e0131353. 
3. UNAIDS. 90-90-90 An ambitious treatment target to help end AIDS epidemic, 2014. 
Available: http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf. 
4. Brennan, A.T., et al., The interplay between CD4 cell count, viral load suppression and 
duration of antiretroviral therapy on mortality in a resource-limited setting. Trop Med Int 
Health, 2013. 18(5): p. 619-31. 
5. Kaulich-Bartz, J., et al., Insurability of HIV positive people treated with antiretroviral therapy 
in Europe: collaborative analysis of HIV cohort studies. AIDS, 2013. 
6. antiretroviral therapy cohort, c., et al., Prognosis of patients treated with cART from 36 
months after initiation, according to current and previous CD4 cell count and plasma HIV-1 
RNA measurements. AIDS, 2009. 23(16): p. 2199-208. 
7. Brinkhof, M.W., et al., Mortality of HIV-infected patients starting antiretroviral therapy in 
sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med, 2009. 6(4): p. 
e1000066. 
8. Braitstein, P., et al., Mortality of HIV-1-infected patients in the first year of antiretroviral 
therapy: comparison between low-income and high-income countries. Lancet, 2006. 
367(9513): p. 817-24. 
9. Boulle, A., et al., Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in 
South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies. PLoS 
Med, 2014. 11(9): p. e1001718. 
10. Rosen, S., M.P. Fox, and C.J. Gill, Patient retention in antiretroviral therapy programs in sub-
Saharan Africa: a systematic review. PLoS Med, 2007. 4(10): p. e298. 
11. Brinkhof, M.W., et al., Early loss of HIV-infected patients on potent antiretroviral therapy 
programmes in lower-income countries. Bull World Health Organ, 2008. 86(7): p. 559-67. 
12. May, M.T., et al., Mortality according to CD4 count at start of combination antiretroviral 
therapy among HIV positive patients followed for up to 15 years after start of treatment: 
collaborative cohort study. Clin Infect Dis, 2016. 
13. Chene, G., et al., Prognostic importance of initial response in HIV-1 infected patients starting 
potent antiretroviral therapy: analysis of prospective studies. Lancet, 2003. 362(9385): p. 
679-86. 
14. Antiretroviral Therapy Cohort, C., et al., Mortality of HIV-infected patients starting potent 
antiretroviral therapy: comparison with the general population in nine industrialized 
countries. Int J Epidemiol, 2009. 38(6): p. 1624-33. 
15. Johnson, L.F., et al., Life expectancies of South African adults starting antiretroviral 
treatment: collaborative analysis of cohort studies. PLoS Med, 2013. 10(4): p. e1001418. 
16. Nachega, J.B., et al., Adherence to highly active antiretroviral therapy assessed by pharmacy 
claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr, 
2006. 43(1): p. 78-84. 
17. Collaboration of Observational, H.I.V.E.R.E.i.E., et al., All-cause mortality in treated HIV-
infected adults with CD4 >/=500/mm3 compared with the general population: evidence from 
a large European observational cohort collaboration. Int J Epidemiol, 2012. 41(2): p. 433-45. 
86 
 
18. Kranzer, K., et al., Antiretroviral treatment cohort analysis using time-updated CD4 counts: 
assessment of bias with different analytic methods. PLoS One, 2011. 6(11): p. e27763. 
19. Karamchand, S., et al., Risk Factors for Incident Diabetes in a Cohort Taking First-Line 
Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy. Medicine 
(Baltimore), 2016. 95(9): p. e2844. 
20. Seyler, C., et al., Risk factors for active tuberculosis after antiretroviral treatment initiation in 
Abidjan. Am J Respir Crit Care Med, 2005. 172(1): p. 123-7. 
21. Lawn, S.D., et al., Burden of tuberculosis in an antiretroviral treatment programme in sub-
Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. 
Aids, 2006. 20(12): p. 1605-12. 
22. Moore, D., et al., Prevalence, incidence and mortality associated with tuberculosis in HIV-
infected patients initiating antiretroviral therapy in rural Uganda. Aids, 2007. 21(6): p. 713-9. 
23. Meintjes, G., et al., Third-line antiretroviral therapy in Africa: effectiveness in a Southern 
African retrospective cohort study. AIDS Res Ther, 2015. 12: p. 39. 
24. Strydom, M.L., D. Corubolo, and C. Nel, Changes in mortality of people living with HIV in 
South Africa and their potential implications for life assurers. 2016. p. 1-33. 
25. Pillay-van Wyk, V., et al., Mortality trends and differentials in South Africa from 1997 to 
2012: second National Burden of Disease Study. Lancet Glob Health, 2016. 4(9): p. e642-53. 
26. Mayosi, B.M., et al., Health in South Africa: changes and challenges since 2009. The Lancet, 
2012. 380(9858): p. 2029-2043. 
 
  
87 
 
5 Appendices 
 
A. Derivation of HIV study data: application of exclusion criteria  
 
Table A1: Derivation of HIV study cohort: application of exclusion criteria 
Total patients 214 741 
Excluded 
Date of ART initiation not determined 95 368 
Baseline viral load <=400 copies/ml 17 024 
Missing baseline CD4 or viral load 6 669 
Age at ART initiation <19 6 063 
Unknown race 5 417 
Dual or triple NRTI therapy 3 284 
Not authorised for ongoing ART 2 448 
ART authorised before January 2000 or after 
March 2013 
1 127 
Baseline regimen is third line  16 
Patients included 77 325 
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B. ART regimen exposure per calendar year in adults, 1998–2013 
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C. Median baseline CD4 count and viral load by year of ART initiation 
 
 
 
 
 
 
90 
 
D. Overall HIV cohort crude mortality 
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E. Overall HIV cohort crude mortality incidence by duration on ART and 
baseline CD4 count 
 
 
 
 
F. Median CD4 count by duration since ART initiation and baseline CD4 count 
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G. Progression in time-updated CD4 count and viral load by baseline CD4 count 
and duration on ART 
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H. Adjusted (multivariate) relative risk ratios (no interactions) 
(*) Indicates the model reference group (baseline or intercept) which had a relative risk of 1.15 [95% 
CI 1.05;1.25] and p-value 1.7106E-03. 
Characteristic  
Adjusted (multivariate) 
relative risk ratio  
[95% CI using robust 
standard errors]  
P value 
(using robust 
standard errors) 
 P value 
<0.05  
 P value 
<0.01  
Current age     
19-39* 
                                         
1  1   
40-49 0.97 [0.93;1]  6.4225E-02 No No 
50-59 0.94 [0.9;0.99]  1.7464E-02 Yes Yes 
60+ 0.72 [0.65;0.78]  2.4014E-13 Yes Yes 
Time since starting ART     
6 1.16 [1.08;1.25]  9.2671E-05 Yes Yes 
12 1.12 [1.04;1.19]  1.6988E-03 Yes Yes 
18 1.09 [1.02;1.17]  1.5744E-02 Yes Yes 
24 1.04 [0.96;1.12]  3.2805E-01 No No 
30 1.02 [0.95;1.11]  5.3930E-01 No No 
36* 
                                         
1 1   
42 0.99 [0.91;1.08]  8.1700E-01 No No 
48 0.94 [0.86;1.04]  2.2773E-01 No No 
54 0.96 [0.87;1.06]  4.2660E-01 No No 
60 0.97 [0.87;1.08]  5.6068E-01 No No 
Current CD4 count and 
viral load     
200+_<=400* 
                                         
1  1   
200+_400+ 2.74 [2.61;2.88]  0.0000E+00 Yes Yes 
<200_400+ 7.12 [6.84;7.41]  0.0000E+00 Yes Yes 
<200_<=400 2.39 [2.25;2.53]  1.7053E-185 Yes Yes 
Gender     
Female* 
                                         
1  1   
Male 0.83 [0.8;0.86]  2.1598E-27 Yes Yes 
Population group     
Black* 
                                         
1  1   
Other 1.63 [1.49;1.79]  2.1620E-25 Yes Yes 
Baseline CD4 count 
(cells/µl)     
<50 1.26 [1.2;1.33]  1.4516E-18 Yes Yes 
50-99 1.16 [1.1;1.23]  4.3955E-08 Yes Yes 
100-199 1.01 [0.96;1.06]  7.7884E-01 No No 
200-249* 
                                         
1  1   
350+ 1.22 [1.1;1.35]  2.3645E-04 Yes Yes 
Baseline viral load 
(copies/ml)     
401-5log 0.82 [0.8;0.85]  3.7049E-28 Yes Yes 
5log-6log* 
                                         
1  1   
6log+ 1.25 [1.17;1.34]  1.5081E-11 Yes Yes 
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Medical scheme     
Same as control* 
                                         
1  1   
Other 1.00 [0.97;1.03]  9.6380E-01 No No 
Year of ART initiation     
<2008 0.87 [0.83;0.9]  8.5305E-13 Yes Yes 
2008+* 
                                         
1  1   
Baseline regimen     
First* 
                                         
1  1   
Second 0.8 [0.73;0.88]  2.5350E-06 Yes Yes 
Current regimen     
First* 
                                         
1  1   
Second 1.09 [1.04;1.15]  1.2663E-03 Yes Yes 
Third 3.98 [2.39;6.62]  1.1210E-07 Yes Yes 
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I. Top 40 models ranked by AICc 
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AICc 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓     96 717  
✓ ✓ ✓ ✓ ✓ ✓ ✓   ✓ ✓ ✓     96 717  
✓   ✓ ✓ ✓ ✓ ✓   ✓ ✓ ✓     96 724  
✓   ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓     96 726  
  ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓     96 747  
  ✓ ✓ ✓ ✓ ✓ ✓   ✓ ✓ ✓     96 748  
    ✓ ✓ ✓ ✓ ✓   ✓ ✓ ✓     96 756  
    ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓     96 758  
✓ ✓ ✓ ✓ ✓   ✓ ✓ ✓ ✓ ✓     96 825  
✓ ✓ ✓ ✓ ✓   ✓   ✓ ✓ ✓     96 825  
✓   ✓ ✓ ✓   ✓   ✓ ✓ ✓     96 836  
✓   ✓ ✓ ✓   ✓ ✓ ✓ ✓ ✓     96 837  
✓ ✓ ✓ ✓ ✓ ✓ ✓     ✓ ✓     96 874  
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓   ✓ ✓     96 874  
✓   ✓ ✓ ✓ ✓ ✓     ✓ ✓     96 882  
✓   ✓ ✓ ✓ ✓ ✓ ✓   ✓ ✓     96 884  
  ✓ ✓ ✓ ✓   ✓ ✓ ✓ ✓ ✓     96 895  
  ✓ ✓ ✓ ✓   ✓   ✓ ✓ ✓     96 897  
  ✓ ✓ ✓ ✓ ✓ ✓ ✓   ✓ ✓     96 903  
  ✓ ✓ ✓ ✓ ✓ ✓     ✓ ✓     96 903  
    ✓ ✓ ✓   ✓   ✓ ✓ ✓     96 912  
    ✓ ✓ ✓   ✓ ✓ ✓ ✓ ✓     96 913  
    ✓ ✓ ✓ ✓ ✓     ✓ ✓     96 913  
    ✓ ✓ ✓ ✓ ✓ ✓   ✓ ✓     96 915  
✓ ✓ ✓ ✓ ✓   ✓     ✓ ✓     96 990  
✓ ✓ ✓ ✓ ✓   ✓ ✓   ✓ ✓     96 990  
✓   ✓ ✓ ✓   ✓     ✓ ✓     97 002  
✓   ✓ ✓ ✓   ✓ ✓   ✓ ✓     97 003  
  ✓ ✓ ✓ ✓   ✓ ✓   ✓ ✓     97 059  
  ✓ ✓ ✓ ✓   ✓     ✓ ✓     97 061  
    ✓ ✓ ✓   ✓     ✓ ✓     97 077  
    ✓ ✓ ✓   ✓ ✓   ✓ ✓     97 078  
✓ ✓ ✓ ✓ ✓ ✓     ✓ ✓ ✓     97 101  
✓ ✓ ✓ ✓ ✓ ✓   ✓ ✓ ✓ ✓     97 101  
✓   ✓ ✓ ✓ ✓     ✓ ✓ ✓     97 112  
✓   ✓ ✓ ✓ ✓   ✓ ✓ ✓ ✓     97 112  
  ✓ ✓ ✓ ✓ ✓   ✓ ✓ ✓ ✓     97 142  
  ✓ ✓ ✓ ✓ ✓     ✓ ✓ ✓     97 143  
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J. Top 50 influential variables and two-way interactions (glmnet) 
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K. Top 50 influential variables and two-way interactions excluding time since starting ART (glmnet) 
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L. Comparison of models with selected interactions 
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AICc 
Testing 
(holdout) 
sample 
Deviance 
7 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
  
✓ ✓ ✓ ✓ 
   
Poisson glm 107 298 21 626 
8 ✓ 
 
✓ ✓ ✓ ✓ ✓ 
 
✓ ✓ ✓ 
      
✓ 
  
Poisson glm  107 351    21 618  
1 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
         
Poisson glm  107 375    21 669  
2 ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
 
✓ ✓ ✓ 
         
Poisson glm  107 408    21 659  
3 ✓ 
 
✓ ✓ ✓ ✓ ✓ 
 
✓ ✓ ✓ 
         
Poisson glm  107 423    21 650  
9 ✓ 
 
✓ ✓ ✓ ✓ ✓ 
 
✓ ✓ 
 
✓ ✓ 
     
✓ 
 
Poisson glm  107 439    21 591  
4 ✓ 
 
✓ ✓ ✓ ✓ ✓ 
 
✓ ✓ 
          
Poisson glm  107 486    21 634  
6 ✓ 
 
✓ ✓ ✓ ✓ ✓ 
 
✓ ✓ 
 
✓ ✓ 
       
Poisson glm  107 497    21 607  
5 ✓ 
 
✓ ✓ ✓ ✓ 
   
✓ 
          
Poisson glm  107 550    21 657  
10 ✓ 
 
✓ ✓ ✓ ✓ ✓ 
 
✓ ✓ 
 
✓ ✓ 
     
✓ ✓ Poisson glm  107 575    21 604  
11 ✓ 
 
✓ ✓ ✓ ✓ ✓ 
 
✓ ✓ 
 
✓ ✓ 
       
Quasipoisson glm  NA    21 607  
12 ✓ 
 
✓ ✓ ✓ ✓ ✓ 
 
✓ ✓ 
 
✓ ✓ 
       
Poisson glmmPQL  NA    21 607  
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M. Comparison of actual relative risk and modelled when predicted on a holdout sample 
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N. Crude (univariate) and adjusted (multivariate) relative risk ratios from 
the final relative risk model  
The reference group, defined by the categories (*) in the table below (also known as 
the baseline or model intercept), corresponds to a relative risk of 92% [95% CI 
0.78;1.08]. Relative risk for other sub-groups is obtained by multiplying the reference 
group relative risk by the corresponding relative risk ratios below. E.g. the relative 
risk for a patient currently aged 19-39, currently on ART for 24 months, with current 
CD4 count ≥ 200 cells/µl and suppressed viral load (≤400 copies/ml), baseline CD4 
count 100-199 cells/µl, baseline viral load 5log-6log copies/ml, population group 
black, female, same medical scheme as the control is obtaining by multiplying 
corresponding adjusted relative risk ratios marked in green (unless 1) resulting in a 
relative risk of 92% × 1.18 × 1.01 × 0.97 = 106%. 
Characteristic 
Crude unadjusted (univariate)  
relative risk ratio 
[95% CI] 
Adjusted (multivariate) 
relative risk ratio 
[Bootstrapped 95% CI] 
Current age     
19-39* 1.00  1.00  
40-49 0.92 [0.88,0.95] 0.97 [0.9,1.05] 
50-59 0.84 [0.8,0.88] 0.96 [0.87,1.08] 
60+ 0.65 [0.6,0.7] 0.72 [0.59,0.89] 
Time since ART initiation (months)     
6 1.18 [1.1,1.26] 1.27 [1.09,1.51] 
12 1.19 [1.11,1.27] 1.34 [1.18,1.57] 
18 1.15 [1.07,1.23] 1.19 [1.06,1.37] 
24 1.09 [1.01,1.16] 1.18 [1.06,1.33] 
30 1.04 [0.97,1.12] 1.19 [1.08,1.31] 
36* 1.00  1.00  
42 0.98 [0.9,1.06] 0.94 [0.85,1.04] 
48 0.92 [0.85,1.01] 0.98 [0.85,1.12] 
54 0.92 [0.84,1.01] 1.05 [0.89,1.23] 
60 0.92 [0.83,1.02] 1.03 [0.84,1.25] 
Current CD4 count and viral load     
200+_<=400* 1.00  1.00  
<200_<=400 2.64 [2.5,2.78] 3.02 [2.18,3.91] 
200+_400+ 2.56 [2.44,2.69] 3.3 [2.8,3.82] 
<200_400+ 7.25 [6.99,7.52] 7.76 [6.87,8.93] 
Gender     
Female* 1.00  1.00  
Male 0.99 [0.96,1.02] 0.83 [0.76,0.89] 
Population group     
Black* 1.00  1.00  
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Other 1.13 [1.03,1.23] 1.59 [1.3,1.88] 
Baseline CD4 count (cells/µl)     
<50 2.11 [2.01,2.21] 1.22 [1.02,1.42] 
50-99 1.85 [1.76,1.94] 1.21 [1.03,1.49] 
100-199 1.27 [1.21,1.33] 1.01 [0.86,1.18] 
200-349* 1.00  1.00  
350+ 1.17 [1.06,1.29] 1.1 [0.69,1.6] 
Baseline viral load     
401-5log 0.72 [0.69,0.74] 0.82 [0.77,0.88] 
5log-6log* 1.00  1.00  
6log+ 1.23 [1.16,1.32] 1.28 [1.12,1.48] 
Medical scheme     
Same as control 1.00  1.00  
Other 0.99 [0.96,1.02] 1.04 [0.96,1.12] 
Time and baseline CD4 interaction     
6:<50   1.48 [1.23,1.8] 
12:<50   1.16 [0.97,1.36] 
18:<50   1.11 [0.96,1.29] 
24:<50   1.01 [0.89,1.15] 
30:<50   0.91 [0.82,1.02] 
36:<50                                       1.00  
42:<50   0.93 [0.82,1.04] 
48:<50   0.84 [0.72,1.01] 
54:<50   0.78 [0.65,0.97] 
60:<50   0.79 [0.63,1.02] 
6:50-99   1.18 [0.96,1.46] 
12:50-99   1 [0.84,1.17] 
18:50-99   0.99 [0.83,1.18] 
24:50-99   0.94 [0.82,1.1] 
30:50-99   0.89 [0.8,0.99] 
36:50-99                                       1.00  
42:50-99   0.94 [0.85,1.07] 
48:50-99   0.94 [0.79,1.14] 
54:50-99   0.88 [0.73,1.09] 
60:50-99   0.83 [0.65,1.06] 
6:100-199   1.19 [0.99,1.44] 
12:100-199   1.02 [0.86,1.18] 
18:100-199   0.99 [0.85,1.13] 
24:100-199   0.97 [0.85,1.08] 
30:100-199   0.92 [0.83,1.01] 
36:100-199                                       1.00  
42:100-199   1.01 [0.91,1.13] 
48:100-199   0.97 [0.83,1.09] 
54:100-199   0.93 [0.78,1.09] 
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60:100-199   0.95 [0.79,1.17] 
6:200-349                                       1.00  
12:200-349                                       1.00  
18:200-349                                       1.00  
24:200-349                                       1.00  
30:200-349                                       1.00  
36:200-349                                       1.00  
42:200-349                                       1.00  
48:200-349                                       1.00  
54:200-349                                       1.00  
60:200-349                                       1.00  
6:350+   1.31 [0.86,1.94] 
12:350+   1.1 [0.76,1.55] 
18:350+   1.07 [0.78,1.5] 
24:350+   1 [0.78,1.43] 
30:350+   0.9 [0.72,1.21] 
36:350+                                      1.00  
42:350+   1.08 [0.81,1.31] 
48:350+   1.14 [0.77,1.6] 
54:350+   1.21 [0.73,1.77] 
60:350+   1.5 [0.79,2.23] 
Time and current CD4 and current 
viral load  interaction     
6:200+_400+   0.77 [0.62,0.94] 
12:200+_400+   0.73 [0.61,0.87] 
18:200+_400+   0.85 [0.71,1.03] 
24:200+_400+   0.78 [0.64,0.92] 
30:200+_400+   0.82 [0.72,0.94] 
36:200+_400+                                       1.00
42:200+_400+   1.01 [0.87,1.17] 
48:200+_400+   0.94 [0.79,1.14] 
54:200+_400+   0.76 [0.59,0.98] 
60:200+_400+   0.75 [0.59,0.98] 
6:<200_400+   0.74 [0.61,0.88] 
12:<200_400+   0.77 [0.67,0.88] 
18:<200_400+   0.86 [0.75,0.99] 
24:<200_400+   0.91 [0.81,1.01] 
30:<200_400+   0.95 [0.87,1.05] 
36:<200_400+                                       1.00
42:<200_400+   1.1 [0.99,1.21] 
48:<200_400+   1.04 [0.89,1.25] 
54:<200_400+   1.11 [0.9,1.34] 
60:<200_400+   1.16 [0.96,1.44] 
6:200+_<=400                                       1.00
12:200+_<=400                                       1.00
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18:200+_<=400                                      1.00
24:200+_<=400                                       1.00
30:200+_<=400                                       1.00
36:200+_<=400                                       1.00
42:200+_<=400                                       1.00
48:200+_<=400                                       1.00
54:200+_<=400                                       1.00
60:200+_<=400                                       1.00
6:<200_<=400   0.52 [0.38,0.72] 
12:<200_<=400   0.66 [0.5,0.91] 
18:<200_<=400   0.88 [0.65,1.22] 
24:<200_<=400   0.86 [0.65,1.12] 
30:<200_<=400   0.89 [0.73,1.1] 
36:<200_<=400                                       1.00
42:<200_<=400   1.6 [1.31,1.98] 
48:<200_<=400   1.15 [0.79,1.75] 
54:<200_<=400   1.06 [0.7,1.68] 
60:<200_<=400   1.08 [0.65,1.71] 
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O. Replicating ART-CC study methodology on study data (adjusted 
relative risk ratios for current age when interacted with population 
group) 
 
 
Characteristic Adjusted relative risk ratio 
Reference group  1.55  
Current age  
20-39        1  
40-49  0.94  
50-59  0.86  
60+  0.73  
Duration of ART  
[0.5,3.5)        1  
[3.5,6.5)  0.70  
6.5+  0.62  
Gender  
Females        1  
Males  0.87  
Population group  
Black        1  
Non-black  3.10  
Medical scheme  
Same as control        1  
Other  0.90  
Baseline CD4 count (cells/µl)  
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<50  1.34  
50-99  1.30  
100-199  1.20  
200-349        1  
350+  1.62  
Baseline viral load (copies/ml)  
401-5log  0.79  
5log-6log        1  
6log+  1.29  
6 month CD4 count (cells/µl)  
<50  4.47  
50-99  2.64  
100-199  1.65  
200-349  1.17  
350+        1  
6 month viral load (copies/ml)  
<10000        1  
10000+  2.73  
Current age (within non-blacks)  
20-39        1  
40-49  0.41  
50-59  0.56  
60+  0.20  
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P. Replicating ART-CC study methodology on study data (relative risk 
ratios by current age and population group) 
 
Other variables are fixed at the model reference group. 
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Q. Sensitivity testing current CD4 bands 
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